10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 FORM 10-Q  

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-34950

SABRA HEALTH CARE REIT, INC.

(Exact Name of Registrant as Specified in Its Charter) 

Maryland	27-2560479
(State of Incorporation)	(I.R.S. Employer Identification No.)

18500 Von Karman Avenue, Suite 550

Irvine, CA 92612

(888) 393-8248

(Address, zip code and telephone number of Registrant)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $.01 par value	SBRA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of October 29, 2020, there were 206,928,325 shares of the registrant’s $0.01 par value Common Stock outstanding.

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES

Index

		Page Numbers
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements:
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Income	5
	Condensed Consolidated Statements of Comprehensive Income (Loss)	6
	Condensed Consolidated Statements of Equity	7
	Condensed Consolidated Statements of Cash Flows	9
	Notes to Condensed Consolidated Financial Statements	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	45
Item 4.	Controls and Procedures	46
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	47
Item 1a.	Risk Factors	47
Item 6.	Exhibits	47
Signatures		49

1

References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.

STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q (this “10-Q”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, potential dispositions, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:

•the ongoing COVID-19 pandemic and measures intended to prevent its spread, including the impact on our tenants, operators and Senior Housing - Managed communities (as defined below);

•our dependence on the operating success of our tenants;

•the potential variability of our reported rental and related revenues following the adoption of Topic 842 (as defined below) on January 1, 2019;

•operational risks with respect to our Senior Housing - Managed communities;

•the effect of our tenants declaring bankruptcy or becoming insolvent;

•our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;

•the impact of litigation and rising insurance costs on the business of our tenants;

•the possibility that Sabra may not acquire the remaining majority interest in the Enlivant Joint Venture (as defined below);

•risks associated with our investments in joint ventures;

•changes in healthcare regulation and political or economic conditions;

•the impact of required regulatory approvals of transfers of healthcare properties;

•competitive conditions in our industry;

•our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;

•    the significant amount of and our ability to service our indebtedness;

•covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;

•increases in market interest rates;

•the potential phasing out of the London Interbank Offered Rate (“LIBOR”) benchmark after 2021;

•our ability to raise capital through equity and debt financings;

•changes in foreign currency exchange rates;

•the relatively illiquid nature of real estate investments;

•the loss of key management personnel;

•uninsured or underinsured losses affecting our properties and the possibility of environmental compliance costs and liabilities;

•the impact of a failure or security breach of information technology in our operations;

•our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws;

•changes in tax laws and regulations affecting REITs (including the potential effects of the Tax Cuts and Jobs Act);

•compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; and

•the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities.

We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019 (our “2019 Annual Report on Form 10-K”) and in Part II, Item 1A, “Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as such risk factors may be amended, supplemented or superseded from time to time

2

by other reports we file with the Securities and Exchange Commission (the “SEC”), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this 10-Q are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-Q or to reflect the occurrence of unanticipated events, unless required by law to do so.

3

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except per share data)  

	September 30, 2020		December 31, 2019
	(unaudited)
Assets
Real estate investments, net of accumulated depreciation of $640,214 and $539,213 as of September 30, 2020 and December 31, 2019, respectively	$	5,306,272	$	5,341,370
Loans receivable and other investments, net	103,820		107,374
Investment in unconsolidated joint venture	293,801		319,460
Cash and cash equivalents	35,034		39,097
Restricted cash	6,815		10,046
Lease intangible assets, net	85,943		101,509
Accounts receivable, prepaid expenses and other assets, net	159,933		150,443
Total assets	$	5,991,618	$	6,069,299
Liabilities
Secured debt, net	$	78,975	$	113,070
Revolving credit facility	56,000		—
Term loans, net	1,039,685		1,040,258
Senior unsecured notes, net	1,248,324		1,248,773
Accounts payable and accrued liabilities	143,742		108,792
Lease intangible liabilities, net	60,552		69,946
Total liabilities	2,627,278		2,580,839
Commitments and contingencies (Note 12)
Equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2020 and December 31, 2019	—		—
Common stock, $0.01 par value; 500,000,000 shares authorized, 206,928,325 and 205,208,018 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	2,069		2,052
Additional paid-in capital	4,101,269		4,072,079
Cumulative distributions in excess of net income	(689,828)		(573,283)
Accumulated other comprehensive loss	(49,170)		(12,388)
Total equity	3,364,340		3,488,460
Total liabilities and equity	$	5,991,618	$	6,069,299

See accompanying notes to condensed consolidated financial statements.

4

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands, except per share data)  

(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenues:
Rental and related revenues	$	100,612	$	110,104	$	319,851	$	339,291
Interest and other income	3,299		3,325		8,756		77,145
Resident fees and services	39,341		36,405		117,908		89,537
Total revenues	143,252		149,834		446,515		505,973
Expenses:
Depreciation and amortization	44,209		43,092		132,579		137,517
Interest	24,904		29,255		75,900		99,181
Triple-net portfolio operating expenses	5,249		5,611		15,481		17,140
Senior housing - managed portfolio operating expenses	27,745		23,979		82,976		60,258
General and administrative	7,216		8,709		24,650		24,952
(Recovery of) provision for loan losses and other reserves	(90)		57		706		1,457
Impairment of real estate	3,154		13,966		3,154		119,102
Total expenses	112,387		124,669		335,446		459,607
Other income (expense):
Loss on extinguishment of debt	(139)		(644)		(531)		(10,763)
Other income	115		215		2,308		385
Net gain (loss) on sales of real estate	2,715		(19)		2,828		1,216
Total other income (expense)	2,691		(448)		4,605		(9,162)
Income before income (loss) from unconsolidated joint venture and income tax benefit (expense)	33,556		24,717		115,674		37,204
Income (loss) from unconsolidated joint venture	2,766		(605)		(13,037)		(5,635)
Income tax benefit (expense)	138		(826)		(1,337)		(2,292)
Net income	36,460		23,286		101,300		29,277
Net income attributable to noncontrolling interest	—		(4)		—		(22)
Net income attributable to common stockholders	$	36,460	$	23,282	$	101,300	$	29,255
Net income attributable to common stockholders, per:
Basic common share	$	0.18	$	0.12	$	0.49	$	0.16
Diluted common share	$	0.18	$	0.12	$	0.49	$	0.16
Weighted-average number of common shares outstanding, basic	205,791,699		190,650,400		205,592,806		183,578,254
Weighted-average number of common shares outstanding, diluted	206,727,167		191,952,389		206,442,674		184,698,411

See accompanying notes to condensed consolidated financial statements.

5

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Net income	$	36,460	$	23,286	$	101,300	$	29,277
Other comprehensive income (loss):
Unrealized (loss) gain, net of tax:
Foreign currency translation (loss) gain	(359)		917		814		924
Unrealized gain (loss) on cash flow hedges	6,830		(9,376)		(37,596)		(32,620)
Total other comprehensive income (loss)	6,471		(8,459)		(36,782)		(31,696)
Comprehensive income (loss)	42,931		14,827		64,518		(2,419)
Comprehensive income attributable to noncontrolling interest	—		(4)		—		(22)
Comprehensive income (loss) attributable to Sabra Health Care REIT, Inc.	$	42,931	$	14,823	$	64,518	$	(2,441)

See accompanying notes to condensed consolidated financial statements.

6

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(dollars in thousands, except per share data)  

(unaudited)

	Three Months Ended September 30, 2019
	Common Stock			Additional Paid-in Capital		Cumulative Distributions in Excess of Net Income		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
	Shares	Amounts
Balance, June 30, 2019	189,515,024	$	1,895	$	3,725,971	$	(460,832)	$	(10,936)	$	3,256,098	$	4,278	$	3,260,376
Net income	—	—		—		23,282		—		23,282		4		23,286
Other comprehensive loss	—	—		—		—		(8,459)		(8,459)		—		(8,459)
Buyout of noncontrolling interest	—	—		4,039		—		—		4,039		(4,239)		(200)
Distributions to noncontrolling interest	—	—		—		—		—		—		(43)		(43)
Amortization of stock-based compensation	—	—		3,930		—		—		3,930		—		3,930
Common stock issuance, net	4,181,877	42		89,644		—		—		89,686		—		89,686
Common dividends ($0.45 per share)	—	—		—		(86,159)		—		(86,159)		—		(86,159)
Balance, September 30, 2019	193,696,901	$	1,937	$	3,823,584	$	(523,709)	$	(19,395)	$	3,282,417	$	—	$	3,282,417
	Three Months Ended September 30, 2020
	Common Stock			Additional Paid-in Capital		Cumulative Distributions in Excess of Net Income		Accumulated Other Comprehensive Income (Loss)		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
	Shares	Amounts
Balance, June 30, 2020	205,560,680	$	2,056	$	4,078,737	$	(663,901)	$	(55,641)	$	3,361,251	$	—	$	3,361,251
Net income	—	—		—		36,460		—		36,460		—		36,460
Other comprehensive income	—	—		—		—		6,471		6,471		—		6,471
Amortization of stock-based compensation	—	—		1,625		—		—		1,625		—		1,625
Common stock issuance, net	1,367,645	13		20,907		—		—		20,920		—		20,920
Common dividends ($0.30 per share)	—	—		—		(62,387)		—		(62,387)		—		(62,387)
Balance, September 30, 2020	206,928,325	$	2,069	$	4,101,269	$	(689,828)	$	(49,170)	$	3,364,340	$	—	$	3,364,340

See accompanying notes to condensed consolidated financial statements.

7

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (CONTINUED)

(dollars in thousands, except per share data)  

(unaudited)

	Nine Months Ended September 30, 2019
	Common Stock			Additional Paid-in Capital		Cumulative Distributions in Excess of Net Income		Accumulated Other Comprehensive Income (Loss)		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
	Shares	Amounts
Balance, December 31, 2018	178,306,528	$	1,783	$	3,507,925	$	(271,595)	$	12,301	$	3,250,414	$	4,333	$	3,254,747
Cumulative effect of Topic 842 adoption	—	—		—		(32,502)		—		(32,502)		—		(32,502)
Net income	—	—		—		29,255		—		29,255		22		29,277
Other comprehensive loss	—	—		—		—		(31,696)		(31,696)		—		(31,696)
Buyout of noncontrolling interest	—	—		4,039		—		—		4,039		(4,239)		(200)
Distributions to noncontrolling interest	—	—		—		—		—		—		(116)		(116)
Amortization of stock-based compensation	—	—		10,474		—		—		10,474		—		10,474
Common stock issuance, net	15,390,373	154		301,146		—		—		301,300		—		301,300
Common dividends ($1.35 per share)	—	—		—		(248,867)		—		(248,867)		—		(248,867)
Balance, September 30, 2019	193,696,901	$	1,937	$	3,823,584	$	(523,709)	$	(19,395)	$	3,282,417	$	—	$	3,282,417
	Nine Months Ended September 30, 2020
	Common Stock			Additional Paid-in Capital		Cumulative Distributions in Excess of Net Income		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
	Shares	Amounts
Balance, December 31, 2019	205,208,018	$	2,052	$	4,072,079	$	(573,283)	$	(12,388)	$	3,488,460	$	—	$	3,488,460
Cumulative effect of Topic 326 adoption	—	—		—		(167)		—		(167)		—		(167)
Net income	—	—		—		101,300		—		101,300		—		101,300
Other comprehensive loss	—	—		—		—		(36,782)		(36,782)		—		(36,782)
Amortization of stock-based compensation	—	—		7,582		—		—		7,582		—		7,582
Common stock issuance, net	1,720,307	17		21,608		—		—		21,625		—		21,625
Common dividends ($1.05 per share)	—	—		—		(217,678)		—		(217,678)		—		(217,678)
Balance, September 30, 2020	206,928,325	$	2,069	$	4,101,269	$	(689,828)	$	(49,170)	$	3,364,340	$	—	$	3,364,340

See accompanying notes to condensed consolidated financial statements.

8

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Nine Months Ended September 30,
	2020		2019
Cash flows from operating activities:
Net income	$	101,300	$	29,277
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	132,579		137,517
Non-cash rental and related revenues	1,340		(12,965)
Non-cash interest income	(1,743)		(1,680)
Non-cash interest expense	6,527		7,846
Stock-based compensation expense	5,651		8,829
Non-cash lease termination income	—		(9,725)
Loss on extinguishment of debt	531		10,763
Provision for loan losses and other reserves	706		1,457
Net gain on sales of real estate	(2,828)		(1,216)
Impairment of real estate	3,154		119,102
Loss from unconsolidated joint venture	13,037		5,635
Distributions of earnings from unconsolidated joint venture	11,318		10,162
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(3,523)		(7,252)
Accounts payable and accrued liabilities	(2,594)		(20,769)
Net cash provided by operating activities	265,455		276,981
Cash flows from investing activities:
Acquisition of real estate	(92,945)		(14,977)
Origination and fundings of loans receivable	(1,651)		(9,441)
Origination and fundings of preferred equity investments	(20,059)		—
Additions to real estate	(32,416)		(15,985)
Repayments of loans receivable	3,095		13,761
Repayments of preferred equity investments	3,399		3,672
Net proceeds from the sales of real estate	8,754		321,715
Distributions in excess of earnings from unconsolidated joint venture	1,305		—
Buyout of noncontrolling interests	—		(200)
Net cash (used in) provided by investing activities	(130,518)		298,545
Cash flows from financing activities:
Net borrowings from (repayments of) revolving credit facility	56,000		(424,000)
Proceeds from issuance of senior unsecured notes	—		297,039
Principal payments on senior unsecured notes	—		(500,000)
Principal payments on secured debt	(2,396)		(2,566)
Payments of deferred financing costs	(819)		(14,001)
Payments related to extinguishment of debt	—		(6,897)
Distributions to noncontrolling interest	—		(116)
Issuance of common stock, net	20,961		302,030
Dividends paid on common stock	(215,747)		(247,222)
Net cash used in financing activities	(142,001)		(595,733)
Net decrease in cash, cash equivalents and restricted cash	(7,064)		(20,207)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(230)		211
Cash, cash equivalents and restricted cash, beginning of period	49,143		59,658
Cash, cash equivalents and restricted cash, end of period	$	41,849	$	39,662
Supplemental disclosure of cash flow information:
Interest paid	$	67,995	$	100,230
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate	$	20,731	$	—
Secured debt assumed by buyers in connection with sales of real estate	$	31,830	$	—

See accompanying notes to condensed consolidated financial statements.

9

SABRA HEALTH CARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1.     BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”) and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

COVID-19

In March 2020, the World Health Organization declared COVID-19 a pandemic, and the United States declared a national emergency with respect to COVID-19. In the intervening months, COVID-19 has spread globally and led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to control its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders. Although some of these governmental restrictions have since been lifted or scaled back, a recent surge of COVID-19 infections has resulted in the re-imposition of certain restrictions and may lead to other restrictions being re-implemented in response to efforts to reduce the spread of COVID-19. These measures may remain in place for a significant amount of time. The COVID-19 pandemic and measures to prevent its spread have negatively impacted and are expected to continue to negatively impact the Company and its operations in a number of ways, including but not limited to:

•Decreased occupancy and increased operating costs for the Company’s tenants and borrowers, which has negatively impacted their operating results and may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to the Company. In some cases, the Company may have to restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to the Company as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of the Company’s investments are not recoverable, which could result in an impairment charge. To date, the impact of COVID-19 on the Company’s skilled nursing/transitional care facility operators has been partially mitigated by the assistance they have received or expect to receive from state and federal assistance programs, including through the CARES Act (as defined and further described below under “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Skilled Nursing Facility Reimbursement Rates” in Part I, Item 2), although these benefits on an individual operator basis vary and may not provide enough relief to meet their rental obligations to the Company. Prior to September 1, 2020, few of these programs were available to the Company’s senior housing operators; as of September 1, 2020, eligible assisted living facility operators may apply for funding through the CARES Act, and the assistance received or expected to be received will partially mitigate the negative impact of COVID-19 on the Company’s eligible assisted living facility operators. As of September 30, 2020, the Company’s tenants and borrowers have continued to pay expected cash rents and debt service obligations consistent with past practice. However, the longer the duration of the COVID-19 pandemic, the more likely that the Company’s tenants and borrowers will begin to default on these obligations. Such defaults could materially and adversely affect the Company’s results of operations and liquidity, in addition to resulting in potential impairment charges.

•Decreased occupancy and increased operating costs within the Company’s Senior Housing - Managed portfolio and in the Company’s 49% equity interest in a joint venture with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, that owns senior housing communities managed by Enlivant (the “Enlivant Joint Venture”), which have negatively impacted and are expected to continue to negatively impact the operating results of these

10

investments. As noted above, as of September 1, 2020, eligible assisted living facility operators may apply for funding through the CARES Act, and the assistance received or expected to be received will partially mitigate the negative impact of COVID-19 on the Company’s Senior Housing - Managed portfolio and the Enlivant Joint Venture. During each of the three and nine months ended September 30, 2020, the Company recognized government grants under the CARES Act of $4.2 million. In addition, on October 1, 2020, the Department of Health and Human Services announced $20 billion of new funding for assisted living facility operators that have already received funds and to those who were previously ineligible. Prolonged deterioration in the operating results for the Company’s investments in its Senior Housing - Managed portfolio and the Enlivant Joint Venture could result in the determination that the full amounts of the Company’s investments are not recoverable, which could result in an impairment charge.

The Company’s financial results as of and for the three and nine months ended September 30, 2020 reflect the results of the Company’s evaluation of the impact of COVID-19 on its business including, but not limited to, its evaluation of potential impairments of long-lived or other assets, measurement of credit losses on financial instruments, evaluation of any lease modifications, evaluation of lease accounting impact, estimates of fair value and the Company’s ability to continue as a going concern.

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2020 and December 31, 2019 and for the three and nine month periods ended September 30, 2020 and 2019. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2020, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the

11

Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2020, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of September 30, 2020, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s condensed consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.

Out of Period Adjustments

During the three months ended September 30, 2020, the Company identified certain historical errors in the recording of depreciation and amortization expense related to the basis difference in the Enlivant Joint Venture and not correctly expensing the allocable portion of the basis difference upon the sale of assets in the Enlivant Joint Venture. These errors impacted the Company’s investment in unconsolidated joint venture and income (loss) from unconsolidated joint venture as well as its condensed consolidated statements of income, condensed consolidated statements of comprehensive income (loss) and condensed consolidated statements of equity since 2018, which impacted the quarterly financial statements and annual periods previously issued. These errors resulted in understating (overstating) previously recorded income (loss) from unconsolidated joint venture and net income by $5.2 million for the six months ended June 30, 2020 and $0.1 million and ($1.7) million for the years ended December 31, 2019 and 2018, respectively. These out of period adjustments were recorded in the third quarter of 2020, resulting in an increase to income from unconsolidated joint venture and net income of $3.6 million. Management evaluated the impact of the errors to the current period and prior period financial statements and determined that the impact was not material to any of the impacted periods.

Government Grants

Government assistance provided to the Company in the form of an income grant, which is not related to long-lived assets and is not required to be repaid, is recognized as grant income when there is reasonable assurance that the grant will be received and the Company will comply with any conditions associated with the grant. Additionally, grants are recognized over the periods in which the Company recognizes the qualifying expenses and/or lost income for which the grants are intended to compensate. As of September 30, 2020, the amount of qualifying expenditures exceeded amounts recognized under the CARES Act, and the Company had complied with all grant conditions. Accordingly, during each of the three and nine months ended September 30, 2020, the Company recognized $1.2 million of grants in resident fees and services and $3.0 million of grants in loss from unconsolidated joint venture in the condensed consolidated statements of income.

Recently Issued Accounting Standards Update

Adopted

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB

12

issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with ASU 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 (collectively, “Topic 326”) on January 1, 2020.

The financial assets within the scope of Topic 326 are the Company’s investments in a direct financing lease and loans receivable, including the portion of unfunded loan commitments expected to be funded. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. Related interest income receivable balances are evaluated separately for collectability, and reserves are established based on management’s estimate of losses.

Upon adoption of these standards, the Company recognized the cumulative effect on the opening balance of the allowance for credit losses in the condensed consolidated balance sheets, which resulted in an increase to cumulative distributions in excess of net income and a decrease to total assets of $0.2 million.

Issued but Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2022. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

3.     RECENT REAL ESTATE ACQUISITIONS

During the nine months ended September 30, 2020, the Company acquired three Senior Housing - Leased communities and one Senior Housing - Managed community. These investments were part of the Company’s proprietary development pipeline, and $20.7 million was previously funded through its preferred equity investments in these developments. During the nine months ended September 30, 2019, the Company acquired two specialty hospitals/other facilities. The consideration was allocated as follows (in thousands):

	Nine Months Ended September 30,
	2020		2019
Land	$	5,800	$	2,040
Building and improvements	104,952		12,652
Tenant origination and absorption costs intangible assets	2,578		234
Tenant relationship intangible assets	347		51
Total consideration	$	113,677	$	14,977

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-

13

average amortization periods as of the respective dates of acquisition of seven years and 25 years, respectively, for acquisitions completed during the nine months ended September 30, 2020, and 15 years and 25 years, respectively, for acquisitions completed during the nine months ended September 30, 2019.

For the three and nine months ended September 30, 2020, the Company recognized $3.4 million and $9.2 million of total revenues, respectively, and $1.4 million and $3.7 million of net income attributable to common stockholders, respectively, from the facilities acquired during the nine months ended September 30, 2020. For each of the three and nine months ended September 30, 2019, the Company recognized $0.2 million of total revenues and $0.2 million of net income attributable to common stockholders from the facilities acquired during the nine months ended September 30, 2019.

4.    INVESTMENT IN REAL ESTATE PROPERTIES

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of September 30, 2020

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	287	32,019	$	3,642,653	$	(360,742)	$	3,281,911
Senior Housing - Leased	64	4,242	707,379		(83,105)		624,274
Senior Housing - Managed	47	4,924	931,655		(134,056)		797,599
Specialty Hospitals and Other	27	1,193	663,982		(61,909)		602,073
	425	42,378	5,945,669		(639,812)		5,305,857
Corporate Level			817		(402)		415
			$	5,946,486	$	(640,214)	$	5,306,272

As of December 31, 2019

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	296	33,290	$	3,701,666	$	(306,565)	$	3,395,101
Senior Housing - Leased	62	3,820	630,688		(72,278)		558,410
Senior Housing - Managed	46	4,809	907,771		(112,893)		794,878
Specialty Hospitals and Other	25	1,193	639,721		(47,124)		592,597
	429	43,112	5,879,846		(538,860)		5,340,986
Corporate Level			737		(353)		384
			$	5,880,583	$	(539,213)	$	5,341,370

	September 30, 2020		December 31, 2019
Building and improvements	$	5,107,022	$	5,042,435
Furniture and equipment	243,265		239,229
Land improvements	1,917		1,534
Land	594,282		597,385
	5,946,486		5,880,583
Accumulated depreciation	(640,214)		(539,213)
	$	5,306,272	$	5,341,370

Operating Leases

As of September 30, 2020, the substantial majority of the Company’s real estate properties (excluding 47 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of September 30, 2020, the leases had a weighted-average remaining term of eight years. The leases generally include

14

provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets and totaled $11.7 million and $10.5 million as of September 30, 2020 and December 31, 2019, respectively, and letters of credit deposited with the Company totaled approximately $86 million and $83 million as of September 30, 2020 and December 31, 2019, respectively. In addition, the Company’s tenants have deposited with the Company $15.4 million and $14.3 million as of September 30, 2020 and December 31, 2019, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $5.0 million and $15.7 million during the three and nine months ended September 30, 2020, respectively, and $4.0 million and $13.0 million during the three and nine months ended September 30, 2019, respectively.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

During the three months ended September 30, 2020, the auditors for Genesis Healthcare, Inc. (“Genesis”) and subsidiaries of Signature Healthcare (“Signature”) that lease facilities from the Company each expressed substantial doubt over the respective abilities of Genesis and Signature to continue as a going concern. Accordingly, the Company concluded that its leases with Genesis and Signature should no longer be accounted for on an accrual basis and wrote off $14.3 million of non-cash rent receivable balances and lease intangibles related to these leases.

For the three and nine months ended September 30, 2020, no tenant relationship represented 10% or more of the Company’s total revenues.

As of September 30, 2020, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

October 1 through December 31, 2020	$	106,516
2021	431,202
2022	412,395
2023	402,083
2024	402,936
Thereafter	1,923,827
	$	3,678,959

Senior Housing - Managed Communities

The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The

15

Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.3 million and $0.7 million for the three and nine months ended September 30, 2020, respectively, and $0.2 million and $0.5 million for the three and nine months ended September 30, 2019, respectively.

Investment in Unconsolidated Joint Venture

The Company has a 49% equity interest in the Enlivant Joint Venture with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, that owns senior housing communities managed by Enlivant. During the nine months ended September 30, 2020, the Enlivant Joint Venture sold 12 senior housing communities for aggregate gross proceeds of $18.2 million, and the Company recorded an aggregate net loss on sale of real estate related to unconsolidated joint venture of $3.3 million. As of September 30, 2020, the Enlivant Joint Venture owned 158 senior housing communities, and the book value of the Company’s investment in the Enlivant Joint Venture was $293.8 million.

Net Investment in Direct Financing Lease

As of September 30, 2020, the Company had a $24.1 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the present value of total rental payments of $2.8 million, plus the estimated purchase price of $24.8 million, less the unearned lease income of $3.3 million and allowance for credit losses of $0.2 million as of September 30, 2020. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $0.7 million and $2.0 million for the three and nine months ended September 30, 2020, respectively, and $0.7 million and $2.0 million for the three and nine months ended September 30, 2019, respectively, and is reflected in interest and other income on the accompanying condensed consolidated statements of income. Upon adoption of Topic 326 on January 1, 2020 and as of the adoption date, the Company recorded a $0.2 million reduction in equity and increase to its allowance for credit losses due to the cumulative effect of the changes contemplated by Topic 326. During the three and nine months ended September 30, 2020, the Company reduced its allowance for credit losses by $1,000 and $38,000, respectively. Future minimum lease payments contractually due under the direct financing lease at September 30, 2020 were as follows: $0.6 million for the remainder of 2020, $2.3 million for 2021 and $0.1 million for 2022.

5.    IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

2020

Asset Held for Sale

As of September 30, 2020, the Company determined that one skilled nursing/transitional care facility with a net book value of $8.9 million met the criteria to be classified as an asset held for sale, and this balance is included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. Subsequent to September 30, 2020, the Company completed the sale of the facility for a gross sales price of $9.0 million.

Impairment of Real Estate

During the nine months ended September 30, 2020, the Company recognized a $3.2 million real estate impairment related to three senior housing communities and one skilled nursing/transitional care facility.

Dispositions

During the nine months ended September 30, 2020, the Company completed the sale of seven skilled nursing/transitional care facilities for aggregate consideration, net of closing costs, of $41.1 million. The net carrying value of the assets and liabilities of these facilities was $38.3 million, which resulted in an aggregate $2.8 million net gain on sale.

During the nine months ended September 30, 2020, the Company recognized $3.9 million of net income, which includes the $2.8 million net gain on sale, and during the nine months ended September 30, 2019, recognized $11.0 million of net loss, which includes $12.8 million of real estate impairment, in each case from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

16

2019

Impairment of Real Estate

During the nine months ended September 30, 2019, the Company recognized a $119.1 million real estate impairment, of which $95.2 million related to the 30 Senior Care Centers facilities that the Company sold and one additional Senior Care Centers facility that the Company transitioned to another operator, and the remaining $23.9 million related to five additional skilled nursing/transitional care facilities that were subsequently sold and four senior housing communities.

Dispositions

During the nine months ended September 30, 2019, the Company completed the sale of 31 skilled nursing/transitional care facilities and seven senior housing communities for aggregate consideration, net of closing costs, of $315.0 million. The net carrying value of the assets and liabilities of these facilities was $313.8 million, which resulted in an aggregate $1.2 million net gain on sale.

During the nine months ended September 30, 2019, the Company recognized $65.1 million of net loss, which includes the $1.2 million net gain on sale and $69.1 million of real estate impairment, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

6.    LOANS RECEIVABLE AND OTHER INVESTMENTS

As of September 30, 2020 and December 31, 2019, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

									September 30, 2020
Investment	Quantity as of September 30, 2020	Property Type	Principal Balance as of September 30, 2020 (1)		Book Value as of September 30, 2020		Book Value as of December 31, 2019		Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of September 30, 2020
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000	$	19,000	10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	3,343		3,353		2,487		8.0	%	7.8	%	09/30/22
Other	17	Multiple	43,973		40,010		42,147		6.8	%	6.9	%	03/01/21- 08/31/28
	19		66,316		62,363		63,634		7.8	%	7.9	%
Allowance for loan losses			—		(1,287)		(564)
			$	66,316	$	61,076	$	63,070
Other Investments:
Preferred Equity	6	Skilled Nursing / Senior Housing	42,533		42,744		44,304		11.3	%	11.3	%	N/A
Total	25		$	108,849	$	103,820	$	107,374	9.2	%	9.3	%

(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

As of September 30, 2020 and December 31, 2019, the Company had four loans receivable investments, with an aggregate principal balance of $2.2 million and $2.3 million, respectively, that were considered to have deteriorated credit quality. As of September 30, 2020 and December 31, 2019, the book value of the outstanding loans with deteriorated credit quality was $0.6 million and $0.8 million, respectively.

The following table presents changes in the accretable yield for the three and nine months ended September 30, 2020 and 2019 (in thousands):

17

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Accretable yield, beginning of period	$	24	$	112	$	39	$	449
Accretion recognized in earnings	(7)		(53)		(22)		(357)
Reduction due to payoff	—		—		—		(33)
Accretable yield, end of period	$	17	$	59	$	17	$	59

During the three months ended September 30, 2020, the Company decreased its allowance for loan losses by $0.1 million, and during the nine months ended September 30, 2020, the Company increased its allowance for loan losses by $0.7 million.

As of September 30, 2020, the Company had a $1.3 million allowance for loan losses. As of September 30, 2020, two loans receivable investments with no book value were on nonaccrual status. As of September 30, 2020, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

As of December 31, 2019, the Company had no asset-specific loan loss reserve and a $0.6 million portfolio-based loan loss reserve. As of December 31, 2019, the Company did not consider any loans receivable investments to be impaired. As of December 31, 2019, two loans receivable investments with no book value were on nonaccrual status. As of December 31, 2019, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

During the three months ended September 30, 2019, the Company recorded no provision for specific loan losses, and during the nine months ended September 30, 2019, the Company recorded a $1.2 million provision for specific loan losses. During the three and nine months ended September 30, 2019, the Company increased its portfolio-based loss reserve by $0.1 million and $0.2 million, respectively.

7.    DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of September 30, 2020 (1)		Principal Balance as of December 31, 2019 (1)		Weighted Average Interest Rate at September 30, 2020 (2)		Maturity Date
Fixed Rate	$	80,124	$	114,777	3.68	%	December 2021 -  August 2051

(1)     Principal balance does not include deferred financing costs, net of $1.1 million and $1.7 million as of September 30, 2020 and December 31, 2019, respectively.

(2)     Weighted average interest rate includes private mortgage insurance.

18

On April 1, 2020, the Company sold two facilities that secured an aggregate $14.2 million of debt, which was assumed by the buyer of the facilities. On August 1, 2020, the Company sold one facility that secured $17.6 million of debt, which was assumed by the buyer of the facility.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	September 30, 2020 (1)		December 31, 2019 (1)
4.80% senior unsecured notes due 2024 (“2024 Notes”)	June 1, 2024	$	300,000	$	300,000
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.88% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		350,000
		$	1,250,000	$	1,250,000

(1)    Principal balance does not include premium, net of $6.7 million and deferred financing costs, net of $8.4 million as of September 30, 2020 and does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019.

The 2024 Notes and the 2029 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 4.80% and 3.90%, respectively, per annum. Interest is payable semiannually on June 1 and December 1 of each year for the 2024 Notes and on April 15 and October 15 of each year for the 2029 Notes.

The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

The obligations under the 2024 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes and 2029 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2024 Notes, 2026 Notes, 2027 Notes and 2029 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of September 30, 2020, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Agreement

On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”).

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $955.0 million in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $105.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024.

As of September 30, 2020, there was $56.0 million outstanding under the Revolving Credit Facility and $944.0 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.45% per annum for LIBOR based borrowings and 0.00% to 0.45% per

19

annum for borrowings at the Base Rate. As of September 30, 2020, the interest rate on the Revolving Credit Facility was 1.25%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that ranges from 0.85% to 1.65% depending on the Debt Ratings.

The Company has interest rate swaps that fix the LIBOR portion of the interest rate for $845.0 million of LIBOR-based borrowings under its U.S. dollar Term Loans at a weighted average rate of 1.24% and an interest rate swap that fixes the CDOR portion of the interest rate for $125.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 0.93%. In addition, CAD $125.0 million of the Canadian dollar Term Loan is designated as a net investment hedge. See Note 8, “Derivative and Hedging Instruments,” for further information.

The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances.

The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a minimum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of September 30, 2020, the Company was in compliance with all applicable financial covenants under the Credit Agreement.

Interest Expense

The Company incurred interest expense of $24.9 million and $75.9 million during the three and nine months ended September 30, 2020, respectively, and $29.3 million and $99.2 million during the three and nine months ended September 30, 2019, respectively. Interest expense includes non-cash interest expense of $2.1 million and $6.5 million for the three and nine months ended September 30, 2020, respectively, and $2.5 million and $7.8 million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020 and December 31, 2019, the Company had $18.1 million and $16.7 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2020 (in thousands): 

	Secured Indebtedness		Revolving Credit     Facility (1)		Term Loans		Senior Notes		Total
October 1 through December 31, 2020	$	655	$	—	$	—	$	—	$	655
2021	17,689		—		—		—		17,689
2022	2,412		—		105,000		—		107,412
2023	2,478		56,000		350,000		—		408,478
2024	2,545		—		593,538		300,000		896,083
Thereafter	54,345		—		—		950,000		1,004,345
Total Debt	80,124		56,000		1,048,538		1,250,000		2,434,662
Premium, net	—		—		—		6,740		6,740
Deferred financing costs, net	(1,149)		—		(8,853)		(8,416)		(18,418)
Total Debt, Net	$	78,975	$	56,000	$	1,039,685	$	1,248,324	$	2,422,984

(1)    Revolving Credit Facility is subject to two six-month extension options.

20

8.    DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. In May 2019, the Company terminated three forward starting interest rate swaps, resulting in a payment to counterparties totaling $12.6 million. The balance of the loss in other comprehensive income will be reclassified to earnings through 2029. As of September 30, 2020, approximately $12.5 million of losses, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):

	September 30, 2020		December 31, 2019
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	1,340,000	$	1,490,000
Denominated in Canadian Dollars (2)	$	250,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	53,239	$	54,489
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	3,061	$	1,811

(1) Balance includes swaps with an aggregate notional value of $400.0 million, which accretes to $600.0 million in January 2023, and two forward starting interest rate swaps and one forward starting interest rate collar with an effective date of January 2021. The forward starting interest rate swaps and forward starting interest rate collar have an aggregate notional amount of $245.0 million. Balance as of September 30, 2020 also includes six forward starting interest rate swaps with an effective date of May 2024 and an aggregate notional amount of $250.0 million.

(2)    Balance as of September 30, 2020 includes two forward starting interest rate swaps with an effective date of January 2021 and an aggregate notional amount of CAD $125.0 million.

21

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2020 and December 31, 2019 (dollars in thousands):    

		Count as of September 30, 2020	Fair Value				Maturity Dates
Type	Designation		September 30, 2020		December 31, 2019			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	—	$	—	$	4,239	N/A	Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swaps	Cash flow	6	3,840		—		2034	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	4,633		3,238		2025	Accounts receivable, prepaid expenses and other assets, net
			$	8,473	$	7,477
Liabilities:
Interest rate swaps	Cash flow	11	$	28,494	$	—	2021- 2024	Accounts payable and accrued liabilities
Forward starting interest rate swaps	Cash flow	4	10,742		494		2024	Accounts payable and accrued liabilities
Forward starting interest rate collars	Cash flow	1	902		132		2024	Accounts payable and accrued liabilities
CAD term loan	Net investment	1	93,538		96,025		2024	Term loans, net
			$	133,676	$	96,651

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and nine months ended September 30, 2020 and 2019 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income (Loss)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019		Income Statement Location
Cash Flow Hedges:
Interest rate products	$	3,836	$	(8,196)	$	(42,826)	$	(27,933)	Interest expense
Net Investment Hedges:
Foreign currency products	(1,044)		1,273		1,544		(3)		N/A
CAD term loan	(1,913)		1,088		2,488		(2,700)		N/A
	$	879	$	(5,835)	$	(38,794)	$	(30,636)

	(Loss) Gain Reclassified from Accumulated Other Comprehensive Income (Loss) into Income
	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019		Income Statement Location
Cash Flow Hedges:
Interest rate products	$	(2,985)	$	1,173	$	(5,148)	$	4,781	Interest expense

During the three and nine months ended September 30, 2020 and 2019, no cash flow hedges were determined to be ineffective.

Derivatives Not Designated as Hedging Instruments

As of September 30, 2020, the Company had one outstanding cross currency interest rate swap, of which a portion was not designated as a hedging instrument, in an asset position with a fair value of $0.3 million and included this amount in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. During the three and nine months ended September 30, 2020, the Company recorded $0.1 million of other expense and $13,000 of other income, respectively, related to this portion of the derivative not designated as a hedging instrument. During the three and nine months

22

ended September 30, 2019, the Company recorded $38,000 and $31,000, respectively, of other income related to a portion of a cross currency interest rate swap not designated as a hedging instrument.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2020 and December 31, 2019 (in thousands):

	As of September 30, 2020
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	8,473	$	—	$	8,473	$	(7,405)	$	—	$	1,068
Offsetting Liabilities:
Derivatives	$	40,138	$	—	$	40,138	$	(7,405)	$	—	$	32,733

	As of December 31, 2019
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544)	$	—	$	82

Credit Risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of September 30, 2020, the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $34.3 million. As of September 30, 2020, the Company has not posted any collateral related to these agreements. If the Company had breached any of these provisions at September 30, 2020, it could have been required to settle its obligations under the agreements at their termination value of $32.7 million.

9.    FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit

23

enhancements as applicable. The Company utilized discount rates ranging from 6% to 16% with a weighted average rate of 12% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized rates ranging from 2% to 3% with a weighted average rate of 3% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2020 and December 31, 2019 whose carrying amounts do not approximate their fair value (in thousands):

	September 30, 2020						December 31, 2019
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	66,316	$	61,076	$	56,956	$	67,527	$	63,070	$	59,832
Preferred equity investments	42,533		42,744		43,039		43,893		44,304		44,493
Financial liabilities:
Senior Notes	1,250,000		1,248,324		1,311,354		1,250,000		1,248,773		1,328,714
Secured indebtedness	80,124		78,975		79,249		114,777		113,070		105,510

(1)    Face value represents amounts contractually due under the terms of the respective agreements.

(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

24

The Company determined the fair value of financial instruments as of September 30, 2020 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Financial assets:
Loans receivable	$	56,956	$	—	$	—	$	56,956
Preferred equity investments	43,039		—		—		43,039
Financial liabilities:
Senior Notes	1,311,354		—		1,311,354		—
Secured indebtedness	79,249		—		—		79,249

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the nine months ended September 30, 2020, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Recurring Basis:
Financial assets:
Forward starting interest rate swaps	$	3,840	$	—	$	3,840	$	—
Cross currency interest rate swaps	4,633		—		4,633		—
Financial liabilities:
Interest rate swaps	28,494		—		28,494		—
Forward starting interest rate swaps	10,742		—		10,742		—
Forward starting interest rate collars	902		—		902		—

10.    EQUITY

Common Stock

On December 11, 2019, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement.

During the three months ended September 30, 2020, the Company sold 1.4 million shares under the ATM Program at an average price of $15.70 per share, generating gross proceeds of $21.4 million, before $0.3 million of commissions. During the nine months ended September 30, 2020, the Company sold 1.6 million shares under the ATM Program at an average price of

$16.26 per share, generating gross proceeds of $25.3 million, before $0.4 million of commissions. As of September 30, 2020, the Company has not utilized the forward feature of the ATM Program and had $314.7 million available under the ATM Program.

The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2020:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 4, 2020	February 14, 2020	$	0.45	February 28, 2020
May 6, 2020	May 18, 2020	$	0.30	May 29, 2020
August 5, 2020	August 17, 2020	$	0.30	August 31, 2020

During the nine months ended September 30, 2020, the Company issued 164,224 shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares to employees as a result of restricted stock unit vestings, the employees’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the nine months ended September 30, 2020 and 2019, the Company incurred $0.9 million and $1.3 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive Loss

The following is a summary of the Company’s accumulated other comprehensive loss (in thousands):

	September 30, 2020		December 31, 2019
Foreign currency translation loss	$	(702)	$	(1,516)
Unrealized loss on cash flow hedges	(48,468)		(10,872)
Total accumulated other comprehensive loss	$	(49,170)	$	(12,388)

11.    EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2020 and 2019 (in thousands, except share and per share amounts):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Numerator
Net income attributable to common stockholders	$	36,460	$	23,282	$	101,300	$	29,255
Denominator
Basic weighted average common shares and common equivalents	205,791,699		190,650,400		205,592,806		183,578,254
Dilutive restricted stock units	935,468		1,301,989		849,868		1,120,157
Diluted weighted average common shares	206,727,167		191,952,389		206,442,674		184,698,411
Net income attributable to common stockholders, per:
Basic common share	$	0.18	$	0.12	$	0.49	$	0.16
Diluted common share	$	0.18	$	0.12	$	0.49	$	0.16

During the three and nine months ended September 30, 2020, approximately 99,700 and 113,300 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three months ended September 30, 2019, no restricted stock units were considered anti-dilutive, and during the nine months ended September 30, 2019, approximately 430 restricted stock units were not included in computing diluted earnings per share because they were considered anti-dilutive.

25

12.    COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of September 30, 2020, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

13.    SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.

Dividend Declaration

On November 5, 2020, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2020 to common stockholders of record as of the close of business on November 16, 2020.

26

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in the “Risk Factors” section in Part I, Item 1A of our 2019 Annual Report on Form 10-K and Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. Also see “Statement Regarding Forward-Looking Statements” preceding Part I.

The following discussion and analysis should be read in conjunction with our accompanying condensed consolidated financial statements and the notes thereto.

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:

•Overview

•Critical Accounting Policies

•Recently Issued Accounting Standards Update

•Results of Operations

•Liquidity and Capital Resources

•Concentration of Credit Risk

•Skilled Nursing Facility Reimbursement Rates

•Obligations and Commitments

•Off-Balance Sheet Arrangements

Overview

We operate as a self-administered, self-managed REIT that, through our subsidiaries, owns and invests in real estate serving the healthcare industry.

Our primary business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector. We primarily generate revenues by leasing properties to tenants and owning properties operated by third-party property managers throughout the United States (“U.S.”) and Canada.

Our investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”) and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments and an investment in an unconsolidated joint venture.

Recent disruptions in the equity and debt markets have significantly increased our cost of capital and have made it difficult to establish market values for potential real estate investments, and accordingly we do not expect to make any material real estate investments as long as these market conditions persist.

Should market conditions improve, we expect to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.

We expect to grow our portfolio primarily through the acquisition of assisted living, independent living and memory care communities in the U.S. and Canada and through the acquisition of skilled nursing/transitional care and behavioral health facilities in the U.S. We have and, should market conditions improve, expect to continue to opportunistically acquire other types of healthcare real estate, originate financing secured directly or indirectly by healthcare facilities and invest in the development of senior housing communities and skilled nursing/transitional care facilities. We also expect to expand our portfolio through the development of purpose-built healthcare facilities through pipeline agreements and other arrangements with select developers. We further expect to work with existing operators to identify strategic development opportunities. These opportunities may involve replacing, renovating or expanding facilities in our portfolio that may have become less competitive and new development opportunities that present attractive risk-adjusted returns. In addition to pursuing acquisitions with triple-net leases, we expect to continue to pursue other forms of investment, including investments in Senior Housing - Managed communities, mezzanine and secured debt investments, and joint ventures for senior housing communities and skilled nursing/

27

transitional care facilities. We also expect to continue to enhance the strength of our investment portfolio by selectively disposing of underperforming facilities or working with new or existing operators to transfer underperforming but promising properties to new operators.

With respect to our debt and preferred equity investments, in general, we originate loans and make preferred equity investments when an attractive investment opportunity is presented and (a) the property is in or near the development phase, (b) the development of the property is completed but the operations of the facility are not yet stabilized or (c) the loan investment will provide capital to existing relationships. A key component of our development strategy related to loan originations and preferred equity investments is having the option to purchase the underlying real estate that is owned by our borrowers (and that directly or indirectly secures our loan investments) or by the entity in which we have an investment. These options become exercisable upon the occurrence of various criteria, such as the passage of time or the achievement of certain operating goals, and the method to determine the purchase price upon exercise of the option is set in advance based on the same valuation methods we use to value our investments in healthcare real estate. This proprietary development pipeline strategy allows us to diversify our revenue streams and build relationships with operators and developers, and provides us with the option to add new properties to our existing real estate portfolio if we determine that those properties enhance our investment portfolio and stockholder value at the time the options are exercisable.

We employ a disciplined, opportunistic approach in our healthcare real estate investment strategy by investing in assets that provide attractive opportunities for dividend growth and appreciation of asset values, while maintaining balance sheet strength and liquidity, thereby creating long-term stockholder value.

We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. We operate through an umbrella partnership, commonly referred to as an UPREIT structure, in which substantially all of our properties and assets are held by Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which we are the sole general partner and a wholly owned subsidiary of ours is currently the only limited partner, or by subsidiaries of the Operating Partnership.

COVID-19

In March 2020, the World Health Organization declared COVID-19 a pandemic, and the United States declared a national emergency with respect to COVID-19. In the intervening months, COVID-19 has spread globally and led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to control its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders. Although some of these governmental restrictions have since been lifted or scaled back, a recent surge of COVID-19 infections has resulted in the re-imposition of certain restrictions and may lead to other restrictions being re-implemented in response to efforts to reduce the spread of COVID-19. These measures may remain in place for a significant amount of time. The COVID-19 pandemic and measures to prevent its spread have negatively impacted and are expected to continue to negatively impact us and our operations in a number of ways, including but not limited to:

•Decreased occupancy and increased operating costs for our tenants and borrowers, which has negatively impacted their operating results and may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to us. In some cases, we may have to restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. To date, the impact of COVID-19 on our skilled nursing/transitional care facility operators has been partially mitigated by the assistance they have received or expect to receive from state and federal assistance programs, including through the CARES Act (as defined and further described below under “—Skilled Nursing Facility Reimbursement Rates”), although these benefits on an individual operator basis vary and may not provide enough relief to meet their rental obligations to us. Prior to September 1, 2020, few of these programs were available to our senior housing operators; as of September 1, 2020, eligible assisted living facility operators may apply for funding through the CARES Act, and the assistance received or expected to be received will partially mitigate the negative impact of COVID-19 on our eligible assisted living facility operators. As of September 30, 2020, our tenants and borrowers have continued to pay expected cash rents and debt service obligations consistent with past practice. However, the longer the duration of the COVID-19 pandemic, the more likely that our tenants and borrowers will begin to default on these obligations. Such defaults could materially and adversely affect our results of operations and liquidity, in addition to resulting in potential impairment charges.

•Decreased occupancy and increased operating costs within our Senior Housing - Managed portfolio and in our 49% equity interest in a joint venture with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, that

28

owns senior housing communities managed by Enlivant (the “Enlivant Joint Venture”), which have negatively impacted and are expected to continue to negatively impact the operating results of these investments. As noted above, as of September 1, 2020, eligible assisted living facility operators may apply for funding through the CARES Act, and the assistance received or expected to be received will partially mitigate the negative impact of COVID-19 on our Senior Housing - Managed portfolio and the Enlivant Joint Venture. During each of the three and nine months ended September 30, 2020, we recognized government grants under the CARES Act of $4.2 million. In addition, on October 1, 2020, the Department of Health and Human Services announced $20 billion of new funding for assisted living facility operators that have already received funds and to those who were previously ineligible. Prolonged deterioration in the operating results for our investments in our Senior Housing - Managed portfolio and the Enlivant Joint Venture could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge.

Our financial results as of and for the three and nine months ended September 30, 2020 reflect the results of our evaluation of the impact of COVID-19 on our business including, but not limited to, our evaluation of potential impairments of long-lived or other assets, measurement of credit losses on financial instruments, evaluation of any lease modifications, evaluation of lease accounting impact, estimates of fair value and our ability to continue as a going concern.

Acquisitions

During the nine months ended September 30, 2020, we acquired three Senior Housing - Leased communities and one Senior Housing - Managed community for an aggregate $113.7 million. See Note 3, “Recent Real Estate Acquisitions,” in the Notes to Condensed Consolidated Financial Statements for additional information regarding these acquisitions.

Dispositions

During the nine months ended September 30, 2020, we completed the sale of seven skilled nursing/transitional care facilities for aggregate consideration, net of closing costs, of $41.1 million. The net carrying value of the assets and liabilities of these facilities was $38.3 million, which resulted in an aggregate $2.8 million net gain on sale.

Critical Accounting Policies

Our condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and in conjunction with the rules and regulations of the SEC. The preparation of our financial statements requires significant management judgments, assumptions and estimates about matters that are inherently uncertain. These judgments affect the reported amounts of assets and liabilities and our disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. With different estimates or assumptions, materially different amounts could be reported in our financial statements. Additionally, other companies may utilize different estimates that may impact the comparability of our results of operations to those of companies in similar businesses. A discussion of the accounting policies that management considers critical in that they involve significant management judgments and assumptions, require estimates about matters that are inherently uncertain and because they are important for understanding and evaluating our reported financial results is included in Part II, Item 7 of our 2019 Annual Report on Form 10-K filed with the SEC. There have been no significant changes to our critical accounting policies during the nine months ended September 30, 2020.

Recently Issued Accounting Standards Update

See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Condensed Consolidated Financial Statements for information concerning recently issued accounting standards updates.

Results of Operations

As of September 30, 2020, our investment portfolio included 425 real estate properties held for investment, one asset held for sale, one investment in a direct financing lease, 19 investments in loans receivable, six preferred equity investments and one investment in an unconsolidated joint venture. As of September 30, 2019, our investment portfolio included 434 real estate properties held for investment, one investment in a direct financing lease, 20 investments in loans receivable, nine preferred equity investments and one investment in an unconsolidated joint venture. In general, we expect that income and expenses related to our portfolio will fluctuate in future periods in comparison to the corresponding prior periods as a result of investment and disposition activity and anticipated future changes in our portfolio. The results of operations presented are not directly comparable due to ongoing acquisition and disposition activity.

29

Comparison of results of operations for the three months ended September 30, 2020 versus the three months ended September 30, 2019 (dollars in thousands):

	Three Months Ended September 30,				Increase / (Decrease)		Percentage Difference		Variance due to Acquisitions, Originations and Dispositions (1)		Remaining Variance (2)
	2020		2019
Revenues:
Rental and related revenues	$	100,612	$	110,104	$	(9,492)	(9)	%	$	1,717	$	(11,209)
Interest and other income	3,299		3,325		(26)		(1)	%	(283)		257
Resident fees and services	39,341		36,405		2,936		8	%	2,429		507
Expenses:
Depreciation and amortization	44,209		43,092		1,117		3	%	854		263
Interest	24,904		29,255		(4,351)		(15)	%	(220)		(4,131)
Triple-net portfolio operating expenses	5,249		5,611		(362)		(6)	%	66		(428)
Senior housing - managed portfolio operating expenses	27,745		23,979		3,766		16	%	1,764		2,002
General and administrative	7,216		8,709		(1,493)		(17)	%	—		(1,493)
(Recovery of) provision for loan losses and other reserves	(90)		57		(147)		(258)	%	—		(147)
Impairment of real estate	3,154		13,966		(10,812)		(77)	%	(3,131)		(7,681)
Other income (expense):
Loss on extinguishment of debt	(139)		(644)		505		(78)	%	(139)		644
Other income	115		215		(100)		(47)	%	—		(100)
Net gain (loss) on sales of real estate	2,715		(19)		2,734		NM		2,734		—
Income (loss) from unconsolidated joint venture	2,766		(605)		3,371		(557)	%	7,538		(4,167)
Income tax benefit (expense)	138		(826)		964		(117)	%	—		964

(1)    Represents the dollar amount increase (decrease) for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 as a result of investments/dispositions made after July 1, 2019.

(2)    Represents the dollar amount increase (decrease) for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 that is not a direct result of investments/dispositions made after July 1, 2019.

Rental and Related Revenues

During the three months ended September 30, 2020, we recognized $100.6 million of rental income compared to $110.1 million for the three months ended September 30, 2019. The $9.5 million net decrease in rental income is primarily related to (i) a $12.1 million net decrease related to leases that we concluded should no longer be accounted for on an accrual basis and (ii) a $1.0 million decrease from properties disposed of after July 1, 2019. The $12.1 million net decrease consists of a $13.1 million decrease in non-cash rental revenues, which includes $14.3 million in write-offs related to Signature Healthcare and Genesis Healthcare, Inc., whose leases are no longer accounted for on an accrual basis as a result of the going concern issues for these tenants, partially offset by a $1.0 million increase in earned cash rents. These decreases are partially offset by (i) a $2.7 million increase from properties acquired after July 1, 2019 and (ii) a $1.0 million increase related to property tax recoveries.

Our reported rental and related revenues may be subject to increased variability in the future as a result of adopting Topic 842. However, there can be no assurances regarding the timing and amount of these collections. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the three months ended September 30, 2020 and 2019.

Interest and Other Income

Interest and other income primarily consists of income earned on our loans receivable investments, preferred returns earned on our preferred equity investments and income on the direct financing lease. During each of the three months ended September 30, 2020 and 2019, we recognized $3.3 million of interest and other income. During the three months ended September 30, 2020, we recognized $0.3 million of lease termination income related to the transition of a specialty hospital to a

30

new operator. In addition, we recognized a $0.7 million decrease in income from investments that were repaid after July 1, 2019, partially offset by a $0.4 million increase in income from investments made after July 1, 2019.

Resident Fees and Services

During the three months ended September 30, 2020, we recognized $39.3 million of resident fees and services compared to $36.4 million for the three months ended September 30, 2019. The $2.9 million net increase is primarily related to (i) a $2.4 million increase from two Senior Housing - Managed communities acquired after July 1, 2019 and (ii) a $1.1 million increase from one Senior Housing - Leased community that was transitioned to a Senior Housing - Managed community in November 2019, partially offset by a $0.6 million decrease from Senior Housing - Managed communities acquired before July 1, 2019 primarily due to decreases in occupancy. Included in resident fees and services is $1.2 million of government grant income recognized under the CARES Act during the three months ended September 30, 2020.

Depreciation and Amortization

During the three months ended September 30, 2020, we incurred $44.2 million of depreciation and amortization expense compared to $43.1 million for the three months ended September 30, 2019. The $1.1 million net increase is primarily due to a $1.6 million increase from properties acquired after July 1, 2019, partially offset by a $0.7 million decrease from properties disposed of after July 1, 2019.

Interest Expense

We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the three months ended September 30, 2020, we incurred $24.9 million of interest expense compared to $29.3 million for the three months ended September 30, 2019. The $4.4 million net decrease is primarily related to (i) a $2.8 million decrease in interest expense related to the redemption of the 5.375% senior unsecured notes due 2023 (the “2023 Notes”) in October 2019, (ii) a $2.1 million decrease in interest expense related to the partial pay down of the U.S. dollar term loans and decrease in interest rates, (iii) a $2.1 million decrease in interest expense related to the borrowings outstanding on the Revolving Credit Facility (as defined below) and decrease in interest rates and (iv) a $0.6 million decrease in non-cash interest expense related to our interest rate hedges, which decreases were partially offset by a $3.6 million increase in interest expense related to the issuance of the 2029 Notes (as defined below).

Triple-Net Portfolio Operating Expenses

During the three months ended September 30, 2020, we recognized $5.2 million of triple-net portfolio operating expenses compared to $5.6 million for the three months ended September 30, 2019. The $0.4 million net decrease is primarily related to property taxes paid during the three months ended September 30, 2019 on facilities that were transitioned to new operators who are now paying the property taxes directly.

Senior Housing - Managed Portfolio Operating Expenses

During the three months ended September 30, 2020, we recognized $27.7 million of Senior Housing - Managed portfolio operating expenses compared to $24.0 million for the three months ended September 30, 2019. The $3.8 million net increase is primarily due to (i) a $1.8 million increase from two Senior Housing - Managed communities acquired after July 1, 2019 and (ii) a $1.0 million increase from one Senior Housing - Leased community that was transitioned to Senior Housing - Managed communities in November 2019. The remaining increase is primarily due to increased supplies and labor needs related to the COVID-19 pandemic.

General and Administrative Expenses

General and administrative expenses include compensation-related expenses as well as professional services, office costs, other costs associated with asset management, and merger and acquisition costs. During the three months ended September 30, 2020, general and administrative expenses were $7.2 million compared to $8.7 million during the three months ended September 30, 2019. The $1.5 million net decrease is primarily related to a $2.3 million decrease in stock-based compensation expense, offset by a $0.9 million increase in employee compensation as a result of increased staffing and employees electing to receive their annual bonus opportunity in cash. The decrease in stock-based compensation expense, from $3.3 million during the three months ended September 30, 2019 to $0.9 million during the three months ended September 30, 2020, is primarily due to a change in performance-based vesting assumptions on management’s equity compensation and employees electing to receive their annual bonus opportunity in cash. We expect stock-based compensation expense to fluctuate from period to period depending upon changes in our stock price and estimates associated with performance-based compensation.

31

(Recovery of) Provision for Loan Losses and Other Reserves

During the three months ended September 30, 2020, we recognized a $0.1 million recovery of loan losses and other reserves, primarily associated with loan loss reserves. During the three months ended September 30, 2019, we recognized a $0.1 million provision for loan losses and other reserves, all of which was associated with loan loss reserves.

Impairment of Real Estate

During the three months ended September 30, 2020, we recognized $3.2 million of impairment of real estate related to three senior housing communities and one skilled nursing/transitional care facility. During the three months ended September 30, 2019, we recognized $14.0 million of impairment of real estate related to three skilled nursing/transitional care facilities that were subsequently sold and four senior housing communities.

Loss on Extinguishment of Debt

During the three months ended September 30, 2020, we recognized a $0.1 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the assumption of a mortgage note by the buyer of the facility that secured the mortgage note. During the three months ended September 30, 2019, we recognized a $0.6 million loss on extinguishment of debt related to the write-off of unamortized deferred financing costs in connection with entering into the Credit Agreement (as defined below).

Other Income

During the three months ended September 30, 2020 and September 30, 2019, we recognized $0.1 million and $0.2 million, respectively, of other income primarily related to settlement payments received related to a legacy Care Capital Properties, Inc. (“CCP”) investment.

Net Gain (Loss) on Sales of Real Estate

During the three months ended September 30, 2020, we recognized an aggregate net gain on the sales of real estate of $2.7 million related to the disposition of a skilled nursing/transitional care facility. During the three months ended September 30, 2019, we recognized $19,000 of selling expenses related to previously completed sales.

Income (Loss) from Unconsolidated Joint Venture

During the three months ended September 30, 2020, we recognized $2.8 million of income from our unconsolidated joint venture compared to $0.6 million of loss for the three months ended September 30, 2019. The $3.4 million net increase is primarily related to (i) a $3.1 million net adjustment to our basis difference in the joint venture as a result of the completion of the joint venture’s strategic program to dispose of 14 senior housing communities and depreciation adjustments, partially offset by a $0.5 million loss on the sale of the final senior housing community in the joint venture’s strategic disposition program during the three months ended September 30, 2020, (ii) $3.0 million of government grant income recognized under the CARES Act and (iii) a $2.0 million decrease in interest expense primarily due to a decrease in interest rates, partially offset by (i) a $2.5 million increase in operating expenses from the facilities owned by the joint venture as of September 30, 2020 due to increased supplies and labor needs related to the COVID-19 pandemic and increased insurance expense and (ii) a $1.7 million decrease in revenue from the facilities owned by the joint venture as of September 30, 2020 primarily due to decreased occupancy.

Income Tax Benefit (Expense)

During the three months ended September 30, 2020, we recognized $0.1 million of income tax benefit compared to $0.8 million of income tax expense for the three months ended September 30, 2019. The decrease is primarily due to lower taxable income from Senior Housing - Managed communities.

32

Comparison of results of operations for the nine months ended September 30, 2020 versus the nine months ended September 30, 2019 (dollars in thousands):

	Nine Months Ended September 30,				Increase / (Decrease)		Percentage Difference		Variance due to Acquisitions, Originations and Dispositions (1)		Remaining Variance (2)
	2020		2019
Revenues:
Rental and related revenues	$	319,851	$	339,291	$	(19,440)	(6)	%	$	(7)	$	(19,433)
Interest and other income	8,756		77,145		(68,389)		(89)	%	(1,794)		(66,595)
Resident fees and services	117,908		89,537		28,371		32	%	7,095		21,276
Expenses:
Depreciation and amortization	132,579		137,517		(4,938)		(4)	%	218		(5,156)
Interest	75,900		99,181		(23,281)		(23)	%	(375)		(22,906)
Triple-net portfolio operating expenses	15,481		17,140		(1,659)		(10)	%	(1,225)		(434)
Senior housing - managed portfolio operating expenses	82,976		60,258		22,718		38	%	5,100		17,618
General and administrative	24,650		24,952		(302)		(1)	%	—		(302)
Provision for loan losses and other reserves	706		1,457		(751)		(52)	%	—		(751)
Impairment of real estate	3,154		119,102		(115,948)		(97)	%	(102,238)		(13,710)
Other income (expense):
Loss on extinguishment of debt	(531)		(10,763)		10,232		(95)	%	(531)		10,763
Other income	2,308		385		1,923		499	%	—		1,923
Net gain on sales of real estate	2,828		1,216		1,612		133	%	1,612		—
Loss from unconsolidated joint venture	(13,037)		(5,635)		(7,402)		131	%	(1,580)		(5,822)
Income tax expense	(1,337)		(2,292)		955		(42)	%	—		955

(1)    Represents the dollar amount increase (decrease) for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 as a result of investments/dispositions made after January 1, 2019.

(2)    Represents the dollar amount increase (decrease) for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 that is not a direct result of investments/dispositions made after January 1, 2019.

Rental and Related Revenues

During the nine months ended September 30, 2020, we recognized $319.9 million of rental income compared to $339.3 million for the nine months ended September 30, 2019. The $19.4 million net decrease in rental income is primarily related to (i) a $14.1 million decrease related to leases that we concluded should no longer be accounted for on an accrual basis, (ii) a $10.1 million decrease from the 21 Holiday communities and one Senior Housing - Leased community that were transitioned to Senior Housing - Managed communities in April 2019 and November 2019, respectively, and (iii) a $7.4 million decrease from properties disposed of after January 1, 2019. The $14.1 million decrease consists of a $13.7 million decrease in non-cash rental revenues, which includes $14.3 million in write-offs related to Signature Healthcare and Genesis Healthcare, Inc., whose leases are no longer accounted for on an accrual basis as a result of the going concern issues for these tenants, and a $0.4 million decrease in earned cash rents. These amounts were partially offset by (i) a $7.4 million increase from properties acquired after January 1, 2019 and (ii) a $2.7 million increase related to property tax recoveries.

Our reported rental and related revenues may be subject to increased variability in the future as a result of adopting Topic 842. However, there can be no assurances regarding the timing and amount of these collections. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the nine months ended September 30, 2020 and 2019.

Interest and Other Income

Interest and other income primarily consists of income earned on our loans receivable investments, preferred returns earned on our preferred equity investments and income on the direct financing lease. During the nine months ended

33

September 30, 2020, we recognized $8.8 million of interest and other income compared to $77.1 million for the nine months ended September 30, 2019. The net decrease of $68.4 million is primarily due to (i) $66.9 million of income related to the transition of the 21 Holiday communities to our Senior Housing - Managed portfolio in April 2019, consisting of a $57.2 million lease termination payment and a $9.7 million gain related to the assumption of fixed assets net of liabilities, and (ii) a $2.4 million decrease in income from investments that were repaid after January 1, 2019, partially offset by a $0.6 million increase in income from investments made after January 1, 2019.

Resident Fees and Services

During the nine months ended September 30, 2020, we recognized $117.9 million of resident fees and services compared to $89.5 million for the nine months ended September 30, 2019. The $28.4 million net increase is primarily related to (i) a $20.6 million increase from the 21 Holiday communities and one Senior Housing - Leased community that were transitioned to Senior Housing - Managed communities in April 2019 and November 2019, respectively, and (ii) a $7.1 million increase from two Senior Housing - Managed communities acquired after January 1, 2019. Included in resident fees and services is $1.2 million of government grant income recognized under the CARES Act during the nine months ended September 30, 2020.

Depreciation and Amortization

During the nine months ended September 30, 2020, we incurred $132.6 million of depreciation and amortization expense compared to $137.5 million for the nine months ended September 30, 2019. The $4.9 million net decrease is primarily due to (i) a $5.7 million decrease due to the acceleration of lease intangible amortization related to the transition of the 21 Holiday communities to Senior Housing - Managed communities in April 2019 and (ii) a $4.3 million decrease from properties disposed of after January 1, 2019, partially offset by a $4.6 million increase from properties acquired after January 1, 2019.

Interest Expense

We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the nine months ended September 30, 2020, we incurred $75.9 million of interest expense compared to $99.2 million for the nine months ended September 30, 2019. The $23.3 million net decrease is primarily related to (i) an aggregate $23.1 million decrease in interest expense related to the redemptions of the 5.5% senior unsecured notes due 2021 (the “2021 Notes”) in June 2019 and the 2023 Notes in October 2019, (ii) a $9.1 million decrease in interest expense related to the borrowings outstanding on the Revolving Credit Facility and decrease in interest rates, (iii) a $6.5 million decrease in interest expense related to the partial pay down of the U.S. dollar term loans and decrease in interest rates and (iv) a $1.3 million decrease in non-cash interest expense related to our interest rate hedges, which decreases were partially offset by an aggregate $17.2 million increase in interest expense related to the issuances of the 2024 Notes (as defined below) and 2029 Notes.

Triple-Net Portfolio Operating Expenses

During the nine months ended September 30, 2020, we recognized $15.5 million of triple-net portfolio operating expenses compared to $17.1 million for the nine months ended September 30, 2019. The $1.7 million net decrease is primarily related to a $1.2 million decrease related to properties disposed of after January 1, 2019 and the remaining decrease is primarily related to property taxes paid during the nine months ended September 30, 2020 on facilities that were transitioned to new operators who are now paying the property taxes directly.

Senior Housing - Managed Portfolio Operating Expenses

During the nine months ended September 30, 2020, we recognized $83.0 million of operating expenses compared to $60.3 million for the nine months ended September 30, 2019. The $22.7 million net increase is primarily due to (i) a $14.8 million increase from the 21 Holiday communities and one Senior Housing - Leased community that were transitioned to Senior Housing - Managed communities in April 2019 and November 2019, respectively, and (ii) a $5.1 million increase from two Senior Housing - Managed communities acquired after January 1, 2019. The remaining increase is primarily due to increased supplies and labor needs related to the COVID-19 pandemic.

General and Administrative Expenses

General and administrative expenses include compensation-related expenses as well as professional services, office costs, other costs associated with asset management, and merger and acquisition costs. During the nine months ended September 30, 2020, general and administrative expenses were $24.7 million compared to $25.0 million during the nine months ended September 30, 2019. The $0.3 million net decrease is primarily related to a $3.2 million decrease in stock-based compensation expense, offset by a $2.7 million increase in employee compensation as a result of increased staffing and employees electing to receive their annual bonus opportunity in cash. The decrease in stock-based compensation expense, from $8.8 million during

34

the nine months ended September 30, 2019 to $5.7 million during the nine months ended September 30, 2020, is primarily due to a change in performance-based vesting assumptions on management’s equity compensation and employees electing to receive their annual bonus opportunity in cash. We expect stock-based compensation expense to fluctuate from period to period depending upon changes in our stock price and estimates associated with performance-based compensation.

Provision for Loan Losses and Other Reserves

During the nine months ended September 30, 2020, we recognized a $0.7 million provision for loan losses and other reserves, primarily associated with loan loss reserves. During the nine months ended September 30, 2019, we recognized a $1.5 million provision for loan losses and other reserves, all of which was associated with loan loss reserves.

Impairment of Real Estate

During the nine months ended September 30, 2020, we recognized $3.2 million of impairment of real estate related to three senior housing communities and one skilled nursing/transitional care facility. During the nine months ended September 30, 2019, we recognized $119.1 million of impairment of real estate, consisting of (i) $95.2 million related to the 30 Senior Care Centers facilities that we sold and one additional Senior Care Centers facility that we transitioned to another operator, which amount included $10.2 million related to our estimated contractual indemnification obligations, and (ii) $23.9 million related to five skilled nursing/transitional care facilities that were subsequently sold and four senior housing communities.

Loss on Extinguishment of Debt

During the nine months ended September 30, 2020, we recognized a $0.5 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the sale of three facilities that secured three mortgage notes. During the nine months ended September 30, 2019, we recognized a $10.8 million loss on extinguishment of debt, consisting of (i) $10.1 million in connection with the redemption of the 2021 Notes, including $6.9 million in payments made to noteholders and legal fees for early redemption and $3.2 million of write-offs associated with unamortized deferred financing and premium costs and (ii) $0.6 million related to the write-off of unamortized deferred financing costs in connection with entering into the Credit Agreement.

Other Income

During the nine months ended September 30, 2020 and September 30, 2019, we recognized $2.3 million and $0.4 million, respectively, of other income primarily related to settlement payments received related to legacy CCP investments.

Net Gain on Sales of Real Estate

During the nine months ended September 30, 2020, we recognized an aggregate net gain on the sales of real estate of $2.8 million related to the disposition of seven skilled nursing/transitional care facilities. During the nine months ended September 30, 2019, we recognized an aggregate net gain on the sales of real estate of $1.2 million related to the disposition of 31 skilled nursing/transitional care facilities and seven senior housing communities.

Loss from Unconsolidated Joint Venture

During the nine months ended September 30, 2020, we recognized $13.0 million of loss from our unconsolidated joint venture compared to $5.6 million of loss for the nine months ended September 30, 2019. The $7.4 million net increase is primarily related to (i) a $6.3 million increase in operating expenses from the facilities owned by the joint venture as of September 30, 2020 primarily due to increased supplies and labor needs related to the COVID-19 pandemic and increased insurance expense, (ii) a $4.9 million depreciation adjustment related to our basis difference in the joint venture, (iii) a $2.4 million decrease in revenues from the facilities owned by the joint venture as of September 30, 2020 primarily due to decreases in occupancy and (iv) a $1.6 million increase in loss on sale primarily related to the sale of 12 senior housing communities, partially offset by (i) a $4.6 million decrease in interest expense primarily due to a decrease in interest rates and (ii) $3.0 million of government grant income recognized under the CARES Act.

Income Tax Expense

During the nine months ended September 30, 2020, we recognized $1.3 million of income tax expense compared to $2.3 million of income tax expense recognized during the nine months ended September 30, 2019. The decrease is primarily due to lower taxable income from Senior Housing - Managed communities.

35

Funds from Operations and Adjusted Funds from Operations

We believe that net income attributable to common stockholders as defined by GAAP is the most appropriate earnings measure. We also believe that funds from operations attributable to common stockholders (“FFO”), as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations attributable to common stockholders (“AFFO”) (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that uses historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income attributable to common stockholders, as defined by GAAP. FFO is defined as net income attributable to common stockholders, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint venture, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint venture, and real estate impairment charges. AFFO is defined as FFO excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, non-cash portion of loss on extinguishment of debt, provision for loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint venture. We believe that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of our operating results among investors and makes comparisons of operating results among REITs more meaningful. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of REITs, they do not represent cash flows from operations or net income attributable to common stockholders as defined by GAAP and should not be considered an alternative to those measures in evaluating our liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to our real estate assets nor do they purport to be indicative of cash available to fund our future cash requirements. Further, our computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other REITs that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define AFFO differently than we do.

36

The following table reconciles our calculations of FFO and AFFO for the three and nine months ended September 30, 2020 and 2019, to net income attributable to common stockholders, the most directly comparable GAAP financial measure, for the same periods (in thousands, except share and per share amounts):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Net income attributable to common stockholders	$	36,460	$	23,282	$	101,300	$	29,255
Depreciation and amortization of real estate assets	44,209		43,092		132,579		137,517
Depreciation and amortization of real estate assets related to noncontrolling interest	—		(14)		—		(93)
Depreciation and amortization of real estate assets related to unconsolidated joint venture	10,391		5,439		21,525		16,102
Net (gain) loss on sales of real estate	(2,715)		19		(2,828)		(1,216)
Net (gain) loss on sales of real estate related to unconsolidated joint venture	(7,537)		—		3,271		1,690
Impairment of real estate	3,154		13,966		3,154		119,102
FFO attributable to common stockholders	83,962		85,784		259,001		302,357
Merger and acquisition costs	5		130		433		192
Stock-based compensation expense	916		3,259		5,651		8,829
Non-cash rental and related revenues	7,907		(4,958)		1,340		(12,965)
Non-cash interest income	(608)		(555)		(1,743)		(1,680)
Non-cash interest expense	2,069		2,523		6,527		7,846
Non-cash portion of loss on extinguishment of debt	139		642		531		3,866
Provision for loan losses and other reserves	(90)		57		706		1,457
Non-cash lease termination income	—		—		—		(9,725)
Other non-cash adjustments related to unconsolidated joint venture	394		777		1,337		2,923
Other non-cash adjustments	110		(3)		137		95
AFFO attributable to common stockholders	$	94,804	$	87,656	$	273,920	$	303,195
FFO attributable to common stockholders per diluted common share	$	0.41	$	0.45	$	1.25	$	1.64
AFFO attributable to common stockholders per diluted common share	$	0.46	$	0.46	$	1.32	$	1.63
Weighted average number of common shares outstanding, diluted:
FFO attributable to common stockholders	206,727,167		191,952,389		206,442,674		184,698,411
AFFO attributable to common stockholders	207,523,386		192,590,320		207,288,178		185,480,674

37

The following table sets forth additional information related to certain other items included in net income attributable to common stockholders above, and the portions of each that are included in FFO and AFFO attributable to common stockholders, which may be helpful in assessing our operating results. Please refer to “—Results of Operations” above for additional information regarding these items (in millions):

	Three Months Ended September 30,												Nine Months Ended September 30,
	2020		2019		2020		2019		2020		2019		2020		2019		2020		2019		2020		2019
	Net Income				FFO				AFFO				Net Income				FFO				AFFO
Rental and related revenues:
Reduction of revenues related to non-cash receivable balances / lease intangible write-offs	$	14.3	$	1.5	$	14.3	$	1.5	$	—	$	—	$	20.8	$	7.4	$	20.8	$	7.4	$	—	$	—
Resident fess and services:
CARES Act grant income	1.2		—		1.2		—		1.2		—		1.2		—		1.2		—		1.2		—
Interest and other income:
Lease termination income	0.3		—		0.3		—		0.3		—		0.3		66.9		0.3		66.9		0.3		57.2
Incremental interest expense related to the redemption of the 2021 Notes	—		—		—		—		—		—		—		1.0		—		1.0		—		1.0
Senior housing - managed portfolio operating expenses:
COVID-19 pandemic related expenses	1.2		—		1.2		—		1.2		—		3.2		—		3.2		—		3.2		—
General and administrative expense:
CCP transition expenses	—		0.1		—		0.1		—		0.1		0.1		0.2		0.1		0.2		0.1		0.2
Merger and acquisition costs	—		0.1		—		0.1		—		—		0.4		0.2		0.4		0.2		—		—
(Recovery of) provision for doubtful accounts	(0.1)		0.1		(0.1)		0.1		—		—		0.7		1.5		0.7		1.5		—		—
Loss on extinguishment of debt	0.1		0.6		0.1		0.6		—		—		0.5		10.8		0.5		10.8		—		6.9
Other income	0.1		0.2		0.1		0.2		0.2		0.2		2.3		0.4		2.3		0.4		2.3		0.4
Loss from unconsolidated joint venture:
CARES Act grant income	3.0		—		3.0		—		3.0		—		3.0		—		3.0		—		3.0		—
Deferred income tax benefit (expense)	0.1		(0.6)		0.1		(0.6)		—		—		(0.3)		(1.7)		(0.3)		(1.7)		—		—
COVID-19 pandemic related expenses	1.3		—		1.3		—		1.3		—		4.1		—		4.1		—		4.1		—

Liquidity and Capital Resources

As of September 30, 2020, we had approximately $979.0 million in liquidity, consisting of unrestricted cash and cash equivalents of $35.0 million and available borrowings under our Revolving Credit Facility of $944.0 million. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion (from U.S. $2.0 billion plus CAD $125.0 million), subject to terms and conditions.

We have filed a shelf registration statement with the SEC that expires in December 2022, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.

On December 11, 2019, we established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of our common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by us through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. During the three months ended September 30, 2020, we sold 1.4 million shares under the ATM Program at an average price of $15.70 per share, generating gross proceeds of $21.4 million, before $0.3 million of commissions. During the nine months ended September 30, 2020, we sold 1.6 million shares under the ATM Program at an average price of $16.26 per share, generating gross proceeds of

38

$25.3 million, before $0.4 million of commissions. As of September 30, 2020, we have not utilized the forward feature of the ATM Program and we had $314.7 million available under the ATM Program. Subject to market conditions, we expect to use proceeds from our ATM Program to reduce our outstanding indebtedness and to finance future investments in properties.

Based on our current assessment of the impact of the COVID-19 pandemic on our company, we believe that our available cash, operating cash flows and borrowings available to us under our Revolving Credit Facility provide sufficient funds for our operations, scheduled debt service payments and dividend requirements for the next twelve months. In addition, we do not believe that the restrictions under our Senior Notes Indentures (as defined below) or Credit Agreement significantly limit our ability to use our available liquidity for these purposes.

Given current market conditions, we expect to use our available liquidity for general corporate purposes and to fund operations as necessary. Recent disruptions in the equity and debt markets have significantly increased our cost of capital and have made it difficult to establish market values for potential real estate investments, and accordingly we do not expect to make any material real estate investments as long as these market conditions persist.

Should market conditions improve, we intend to once again invest in additional healthcare properties as suitable opportunities arise and adequate sources of financing are available. We expect that future investments in properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed, in whole or in part, by our existing cash, borrowings available to us under our Revolving Credit Facility, future borrowings or the proceeds from issuances of common stock (including through our ATM Program), preferred stock, debt or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae, Freddie Mac and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions. We also use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk.

Cash Flows from Operating Activities

Net cash provided by operating activities was $265.5 million for the nine months ended September 30, 2020. Operating cash inflows were derived primarily from the rental payments received under our lease agreements, resident fees and services net of the corresponding operating expenses and interest payments from borrowers under our loan investments. Operating cash outflows consisted primarily of interest payments on borrowings and payment of general and administrative expenses, including corporate overhead. We expect our annualized cash flows provided by operating activities to fluctuate as a result of completed investment and disposition activity and anticipated future changes in our portfolio.

Cash Flows from Investing Activities

During the nine months ended September 30, 2020, net cash used in investing activities was $130.5 million and included $92.9 million used for the acquisition of four facilities, $32.4 million used for additions to real estate, $20.1 million used to provide funding for a preferred equity investment and $1.7 million used to provide additional funding for existing loans receivable, partially offset by $8.8 million in sales proceeds related to the disposition of seven real estate facilities, $3.4 million in repayments of preferred equity investments, $3.1 million in repayments of loans receivable and $1.3 million in distributions in excess of earnings from unconsolidated joint venture.

Cash Flows from Financing Activities

During the nine months ended September 30, 2020, net cash used in financing activities was $142.0 million and included $215.7 million of dividends paid to stockholders, $2.4 million of principal repayments on secured debt and $0.8 million of payments of deferred financing costs, partially offset by $21.0 million of net proceeds from shares sold through our ATM Program, net of payroll tax payments related to the issuance of common stock pursuant to equity compensation arrangements. In addition, during the nine months ended September 30, 2020, we borrowed a net amount of $56.0 million on our Revolving Credit Facility.

In March 2020, we announced a significant reduction to our quarterly dividend, which reduction was implemented by our board of directors on May 6, 2020 when it declared a quarterly cash dividend of $0.30 per share of common stock. We took this step to help focus our capital resources and liquidity on maintaining our balance sheet strength and enhancing our ability to assist our operators in their time of need. We expect that our board of directors will re-evaluate the quarterly dividend once the COVID-19 pandemic has passed.

Please see the accompanying condensed consolidated statements of cash flows for details of our operating, investing and financing cash activities.

39

Loan Agreements

2024 Notes. On May 29, 2019, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of Sabra (together, the “Issuers”) issued $300.0 million aggregate principal amount of 4.80% senior notes due 2024 (the “2024 Notes”), providing net proceeds of approximately $295.3 million after deducting underwriting discounts and other offering expenses. In connection with the October 2019 redemption of other senior notes of the Issuers, Sabra Capital Corporation’s obligations as a co-issuer were automatically released and discharged.

2026 and 2027 Notes. In connection with our merger with CCP, on August 17, 2017, Sabra assumed $500 million aggregate principal amount of 5.125% senior notes due 2026 (the “2026 Notes”) and $100 million aggregate principal amount of 5.88% senior notes due 2027 (the “2027 Notes”).

2029 Notes. On October 7, 2019, the Issuers issued $350.0 million aggregate principal amount of 3.90% senior notes due 2029 (the “2029 Notes” and, together with the 2024 Notes, the 2026 Notes and the 2027 Notes, the “Senior Notes”), providing net proceeds of $340.5 million after deducting underwriting discounts and other offering expenses. In connection with the October 2019 redemption of other senior notes of the Issuers, Sabra Capital Corporation’s obligations as a co-issuer were automatically released and discharged.

See Note 7, “Debt,” in the Notes to Condensed Consolidated Financial Statements for additional information concerning the Senior Notes, including information regarding the indentures and agreements governing the Senior Notes (the “Senior Notes Indentures”). As of September 30, 2020, we were in compliance with all applicable covenants under the Senior Notes Indentures.

Guarantor Financial Information. The 2024 Notes are issued by the Operating Partnership and fully and unconditionally guaranteed, jointly and severally, by us and one of our non-operating subsidiaries, subject to release under certain customary circumstances as described below. In connection with the Operating Partnership’s assumption of the 2026 Notes, we have fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. The 2029 Notes are issued by the Operating Partnership and guaranteed, fully and unconditionally, by us.

These guarantees are subordinated to all existing and future senior debt and senior guarantees of the applicable guarantors and are unsecured. We conduct all of our business through and derive virtually all of our income from our subsidiaries. Therefore, our ability to make required payments with respect to our indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of our subsidiaries and our ability to receive funds from our subsidiaries.

A guarantor will be automatically and unconditionally released from its obligations under the guarantee with respect to the 2024 Notes in the event of:

•Any sale of the subsidiary guarantor or of all or substantially all of its assets;

•A merger or consolidation of the subsidiary guarantor with the Operating Partnership or Sabra, provided that the surviving entity remains a guarantor;

•The requirements for legal defeasance or covenant defeasance or to discharge the indentures governing the 2024 Notes have been satisfied;

•A liquidation or dissolution, to the extent permitted under the indenture governing the 2024 Notes, of the subsidiary guarantor;

•The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty; or

•If the subsidiary guarantor is not a guarantor or is not otherwise liable in respect of any obligations under any credit facility (as defined in the indenture governing the 2024 Notes) of us or any of our subsidiaries.

We will be automatically and unconditionally released from our obligations under the guarantee with respect to the 2026 Notes in the event of:

•A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes;

•A merger or consolidation, provided that the surviving entity remains a guarantor; or

•The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied.

Pursuant to amendments to Regulation S-X, the following aggregate summarized financial information is provided for Sabra, the Operating Partnership and Sabra Health Care, L.L.C. (the guarantor subsidiary of the 2024 Notes). This aggregate summarized financial information has been prepared from the books and records maintained by us, the Operating Partnership

40

and Sabra Health Care, L.L.C. The aggregate summarized financial information does not include the investments in non-guarantor subsidiaries nor the earnings from non-guarantor subsidiaries and therefore is not necessarily indicative of the results of operations or financial position had the Operating Partnership and Sabra Health Care, L.L.C. operated as independent entities. Intercompany transactions have been eliminated. The aggregate summarized balance sheet information as of September 30, 2020 and December 31, 2019 and aggregate summarized statement of loss information for the nine months ended September 30, 2020 is as follows (in thousands):

	September 30, 2020		December 31, 2019
Total assets	$	49,462	$	52,597
Total liabilities	2,336,531		2,241,501
	Nine Months Ended September 30, 2020
Total revenues	342
Total expenses	88,917
Net loss	(88,963)
Net loss attributable to common stockholders	(88,963)

Credit Agreement. Effective on September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”).

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $955.0 million in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $105.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024.

The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by us and one of our non-operating subsidiaries, subject to release under certain customary circumstances.

See Note 7, “Debt,” in the Notes to Condensed Consolidated Financial Statements for additional information concerning the Credit Agreement, including information regarding covenants contained in the Credit Agreement. As of September 30, 2020, we were in compliance with all applicable covenants under the Credit Agreement.

Secured Indebtedness

As of September 30, 2020 and December 31, 2019, 13 and 16 of our properties held for investment were subject to secured indebtedness to third parties, respectively. As of September 30, 2020 and December 31, 2019, our secured debt consisted of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of September 30, 2020 (1)		Principal Balance as of December 31, 2019 (1)		Weighted Average Interest Rate at September 30, 2020 (2)		Maturity Date
Fixed Rate	$	80,124	$	114,777	3.68	%	December 2021 -  August 2051

(1)    Principal balance does not include deferred financing costs, net of $1.1 million and $1.7 million as of September 30, 2020 and December 31, 2019, respectively.

(2)    Weighted average interest rate includes private mortgage insurance.

41

Capital Expenditures

We had $32.4 million and $16.0 million of capital expenditures for the nine months ended September 30, 2020 and 2019, respectively. There are no present plans for the improvement or development of any unimproved or undeveloped property; however, from time to time we may agree to fund improvements our tenants make at our facilities. Accordingly, we anticipate that our aggregate capital expenditure requirements for the next 12 months will principally be for improvements to our facilities and will not exceed $64 million, of which $31 million will directly result in incremental rental income.

Dividends

We paid dividends of $215.7 million on our common stock during the nine months ended September 30, 2020. On November 5, 2020, our board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2020 to common stockholders of record as of November 16, 2020.

Concentration of Credit Risk

Concentrations of credit risk arise when a number of operators, tenants or obligors related to our investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to us, to be similarly affected by changes in economic conditions. We regularly monitor our portfolio to assess potential concentrations of risks.

Management believes our current portfolio is reasonably diversified across healthcare related real estate and geographical location and does not contain any other significant concentration of credit risks. Our portfolio of 425 real estate properties held for investment as of September 30, 2020 is diversified by location across the United States and Canada.

For the three and nine months ended September 30, 2020, no tenant relationship represented 10% or more of our total revenues.

Skilled Nursing Facility Reimbursement Rates

For the nine months ended September 30, 2020 (excluding one-time lease termination income of $0.3 million), 53.1% of our revenues was derived directly or indirectly from skilled nursing/transitional care facilities. Medicare reimburses skilled nursing facilities for Medicare Part A services under the Prospective Payment System (“PPS”), as implemented pursuant to the Balanced Budget Act of 1997 and modified pursuant to subsequent laws, most recently the Patient Protection and Affordable Care Act of 2010. PPS regulations predetermine a payment amount per patient, per day, based on a market basket index calculated for all covered costs.

Prior to October 1, 2019, the amount to be paid was determined by classifying each patient into one of 66 Resource Utilization Group (“RUG”) categories that represented the level of services required to treat different conditions and levels of acuity. The system of 66 RUG categories, or Resource Utilization Group, version IV (“RUG IV”), became effective as of October 1, 2010. RUG IV resulted from research performed by the Centers for Medicare & Medicaid Services (“CMS”) and was part of CMS’s continuing effort to increase the correlation of the cost of services to the condition of individual patients.

On July 31, 2018, CMS issued a final rule, CMS-1696-F, which includes changes to the case-mix classification system used under the PPS and fiscal year 2019 Medicare payment updates.

CMS-1696-F includes a new case-mix classification system called the skilled nursing facility Patient-Driven Payment Model (“PDPM”) that became effective on October 1, 2019. PDPM reflects significant changes to the Resident Classification System, Version I (“RCS-I”) that was being considered to replace RUG IV as outlined in an Advanced Notice of Proposed Rulemaking released by CMS in May 2017.

PDPM focuses on clinically relevant factors, rather than volume-based service, for determining Medicare payment. PDPM adjusts Medicare payments based on each aspect of a resident’s care, most notably for non-therapy ancillaries, which are items and services not related to the provision of therapy such as drugs and medical supplies, thereby more accurately addressing costs associated with medically complex patients. It further adjusts the skilled nursing facility per diem payments to reflect varying costs throughout the stay and incorporates safeguards against potential financial incentives to ensure that beneficiaries receive care consistent with their unique needs and goals.

On July 30, 2019, CMS released final fiscal year 2020 Medicare rates for skilled nursing facilities providing an estimated net increase of 2.4% over fiscal year 2019 payments (comprised of a market basket increase of 2.8% less the productivity adjustment of 0.4%). The new payment rates became effective on October 1, 2019.

42

On July 31, 2020, CMS released final fiscal year 2021 Medicare rates for skilled nursing facilities providing an estimated net increase of 2.2% over fiscal year 2020 payments (comprised of a market basket increase of 2.2% and no productivity adjustment). The new payment rates became effective on October 1, 2020.

In response to the COVID-19 pandemic, several federal relief packages were approved that could benefit our tenants, especially our tenants that operate skilled nursing/transitional care facilities.

On March 18, 2020, President Trump signed into law the Families First Coronavirus Response Act (“Families First Act”). Under the Families First Act, a temporary 6.2% increase in Federal Medical Assistance Percentages (“FMAP”) was approved retroactive to January 1, 2020, and several states have directed FMAP funds to skilled nursing/transitional care facilities.

On March 27, 2020, President Trump signed into law The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act provides for a $175 billion fund for eligible health care providers, which includes skilled nursing/transitional care operators, and as of September 1, 2020 also includes assisted living facility operators. The CARES Act also includes a temporary suspension of 2% Medicare sequestration cut beginning May 1, 2020 through December 31, 2020, a deferral of the employer’s Social Security remittances through December 31, 2020, and the establishment of the Paycheck Protection Program, a Small Business Administration loan to businesses with fewer than 500 employees that may be partially forgivable.

In addition to the above, there have been other actions taken that benefit skilled nursing/transitional care operators, including the waiver of the requirement for skilled nursing/transitional care patients to have stayed in a hospital for three days in order for services rendered in a skilled nursing/transitional care facility to qualify for Medicare Part A, the acceleration and advance of three months of Medicare billing, and relaxation of certification requirements for employees performing non-clinical services in these facilities.

The Department of Health and Human Services (“HHS”) extended the COVID-19 Public Health Emergency for another 90 days, effective October 23, 2020, which allows HHS to continue providing temporary regulatory waivers and new rules to equip skilled nursing facilities and some assisted living operators with flexibility to respond to the COVID-19 pandemic. The extension of the COVID-19 Public Health Emergency also extends the Federal Medical Assistance Percentages funding increase through March 31, 2021.

Obligations and Commitments

The following table summarizes our contractual obligations and commitments in future years, including our secured indebtedness to third parties on certain of our properties, our Revolving Credit Facility, our Term Loans, our Senior Notes and our operating leases. The following table is presented as of September 30, 2020 (in thousands):

			October 1 through December 31, 2020				Year Ending December 31,
	Total				2021		2022		2023		2024		After 2024
Secured indebtedness (1)	$	105,872	$	1,280	$	20,062	$	4,161	$	4,161	$	4,161	$	72,047
Revolving Credit Facility (2)	65,543		818		3,243		3,243		58,239		—		—
Term Loans (3)	1,136,413		6,292		26,177		130,370		370,390		603,184		—
Senior Notes (4)	1,635,885		16,715		59,055		59,055		59,055		359,055		1,082,950
Operating leases	2,561		108		445		467		507		529		505
Total	$	2,946,274	$	25,213	$	108,982	$	197,296	$	492,352	$	966,929	$	1,155,502

(1)Secured indebtedness includes principal payments and interest payments through the applicable maturity dates. Total interest on secured indebtedness, based on contractual rates, is $25.7 million, which is attributable to fixed rate debt.

(2)Revolving Credit Facility includes interest payments and payments related to the facility fee due to the lenders based on the amount of commitments under the Revolving Credit Facility through the maturity date (assuming no exercise of our two six-month extension options) totaling $9.5 million.

(3)Term Loans includes interest payments through the applicable maturity dates totaling $87.9 million, which reflects the impact of interest rate swaps.

(4)Senior Notes includes interest payments through the applicable maturity dates totaling $385.9 million.

In addition to the above, as of September 30, 2020, we have committed to provide up to $2.2 million of future funding related to four loans receivable investments with maturity dates ranging from March 2021 to December 2022.

Off-Balance Sheet Arrangements

We have a 49% interest in an unconsolidated joint venture. See Note 4, “Investment in Real Estate Properties—Investment in Unconsolidated Joint Venture,” in the Notes to Condensed Consolidated Financial Statements for additional

43

information. We have no other off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to various market risks, primarily related to adverse changes in interest rates and the exchange rate for Canadian dollars. We use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. See Note 8, “Derivative and Hedging Instruments,” in the Notes to Condensed Consolidated Financial Statements for further discussion of our derivative instruments.

Interest rate risk. As of September 30, 2020, our indebtedness included $1.3 billion aggregate principal amount of Senior Notes outstanding, $80.1 million of secured indebtedness to third parties on certain of the properties that our subsidiaries own, $1.0 billion in Term Loans and $56.0 million outstanding under the Revolving Credit Facility. As of September 30, 2020, we had $1.1 billion of outstanding variable rate indebtedness and $944.0 million available for borrowing under our Revolving Credit Facility. Additionally, as of September 30, 2020, our share of unconsolidated joint venture debt was $376.0 million, all of which was variable rate indebtedness.

We expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness. We also may manage, or hedge, interest rate risks related to our borrowings through interest rate swap agreements. As of September 30, 2020, we had interest rate swaps that fix the LIBOR portion of the interest rate for $845.0 million of LIBOR-based borrowings under the U.S. dollar Term Loans at a weighted average rate of 1.24% and an interest rate swap that fixes the Canadian Dollar Offered Rate (“CDOR”) portion of the interest rate for CAD $125.0 million of CDOR-based borrowings under the Canadian dollar Term Loan at a rate of 0.93%. As of September 30, 2020, our share of unconsolidated joint venture debt included $368.4 million of LIBOR-based borrowings subject to interest rate cap agreements that cap the LIBOR portion of the interest rate at a weighted average rate of 2.89%.

From time to time, we may borrow under the Revolving Credit Facility to finance future investments in properties, including any improvements or renovations of current or newly acquired properties, or for other purposes. Because borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at our option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0%, the interest rate we will be required to pay on any such borrowings will depend on then applicable rates and may vary. An increase in interest rates could make the financing of any investment by us more costly. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness.

As of September 30, 2020, the index underlying our variable rate debt and our share of unconsolidated joint venture debt was below 100 basis points. Assuming a 100 basis point increase in the index or a reduction of this index to zero, and after giving effect to the impact of interest rate derivative instruments, net income would decrease by $5.4 million or increase by $0.8 million, respectively, for the twelve months following September 30, 2020.

Foreign currency risk. We are exposed to changes in foreign exchange rates as a result of our investments in Canadian real estate. Our foreign currency exposure is partially mitigated through the use of Canadian dollar denominated debt totaling CAD $145.7 million and cross currency swap instruments. Based on our operating results for the three months ended September 30, 2020, if the value of the Canadian dollar relative to the U.S. dollar were to increase or decrease by 10% compared to the average exchange rate during the three months ended September 30, 2020, our cash flows would have decreased or increased, as applicable, by $0.1 million.

44

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, management, including our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based upon, and as of the date of, the evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2020 to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

45

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None of the Company or any of its subsidiaries is a party to, and none of their respective property is the subject of, any material legal proceeding, although we are from time to time party to legal proceedings that arise in the ordinary course of our business.

ITEM 1A. RISK FACTORS

There have been no material changes in our assessment of our risk factors from those set forth in Part I, Item 1A of our 2019 Annual Report on Form 10-K, as updated by the risk factor set forth in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.

ITEM 6. EXHIBITS

Ex.	Description
2.1	Agreement and Plan of Merger, dated as of May 7, 2017, by and among Sabra Health Care REIT, Inc., PR Sub, LLC, Sabra Health Care Limited Partnership, Care Capital Properties, Inc. and Care Capital Properties, LP (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on May 8, 2017).
3.1	Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated October 20, 2010, filed with the State Department of Assessments and Taxation of the State of Maryland on October 21, 2010 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on October 26, 2010).
3.1.1	Articles of Amendment to the Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated as of July 31, 2017 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on July 31, 2017).
3.1.2	Articles of Amendment to the Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated as of June 9, 2020 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on June 12, 2020).
3.2	Amended and Restated Bylaws of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on March 14, 2019).
22.1	List of Subsidiary Issuers and Guarantors of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 22.1 of the Quarterly Report on Form 10-Q filed by Sabra Health Care REIT, Inc. on August 5, 2020).
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

46

Ex.	Description
104*	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

*	Filed herewith.
**	Furnished herewith.

47

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SABRA HEALTH CARE REIT, INC.
Date: November 5, 2020	By:	/S/    RICHARD K. MATROS
		Richard K. Matros
		Chairman, President and
		Chief Executive Officer
		(Principal Executive Officer)
Date: November 5, 2020	By:	/S/    HAROLD W. ANDREWS, JR.
		Harold W. Andrews, Jr.
		Executive Vice President,
		Chief Financial Officer and Secretary
		(Principal Financial and Accounting Officer)

48

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Richard K. Matros, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2020

/S/    RICHARD K. MATROS

Richard K. Matros

Chairman, President and
Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Harold W. Andrews, Jr., certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2020

/S/    HAROLD W. ANDREWS, JR.

Harold W. Andrews, Jr.

Executive Vice President,
Chief Financial Officer and Secretary

EX-32.1

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three and nine months ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard K. Matros, as Chairman, President and Chief Executive Officer of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: November 5, 2020

/S/    RICHARD K. MATROS

Richard K. Matros

Chairman, President and
Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three and nine months ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Harold W. Andrews, Jr., the Executive Vice President, Chief Financial Officer and Secretary of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: November 5, 2020

/S/    HAROLD W. ANDREWS, JR.

Harold W. Andrews, Jr.

Executive Vice President,
Chief Financial Officer and Secretary

XML

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 29, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-34950
Entity Registrant Name	SABRA HEALTH CARE REIT, INC.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	27-2560479
Entity Address, Address Line One	18500 Von Karman Avenue, Suite 550
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92612
City Area Code	888
Local Phone Number	393-8248
Title of 12(b) Security	Common stock, $.01 par value
Trading Symbol	SBRA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		206,928,325
Document Fiscal Period Focus	Q3
Amendment Flag	false
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001492298

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets
Real estate investments, net of accumulated depreciation of $640,214 and $539,213 as of September 30, 2020 and December 31, 2019, respectively	$ 5,306,272	$ 5,341,370
Loans receivable and other investments, net	103,820	107,374
Investment in unconsolidated joint venture	293,801	319,460
Cash and cash equivalents	35,034	39,097
Restricted cash	6,815	10,046
Lease intangible assets, net	85,943	101,509
Accounts receivable, prepaid expenses and other assets, net	159,933	150,443
Total assets	5,991,618	6,069,299
Liabilities
Secured debt, net	78,975	113,070
Revolving credit facility	56,000	0
Term loans, net	1,039,685	1,040,258
Senior unsecured notes, net	1,248,324	1,248,773
Accounts payable and accrued liabilities	143,742	108,792
Lease intangible liabilities, net	60,552	69,946
Total liabilities	2,627,278	2,580,839
Commitments and contingencies (Note 12)
Equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2020 and December 31, 2019	0	0
Common stock, $0.01 par value; 500,000,000 shares authorized, 206,928,325 and 205,208,018 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	2,069	2,052
Additional paid-in capital	4,101,269	4,072,079
Cumulative distributions in excess of net income	(689,828)	(573,283)
Accumulated other comprehensive loss	(49,170)	(12,388)
Total equity	3,364,340	3,488,460
Total liabilities and equity	$ 5,991,618	$ 6,069,299

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets
Accumulated depreciation	$ 640,214	$ 539,213
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2020 and December 31, 2019
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	10,000,000	10,000,000
Shares issued (in shares)	0	0
Shares outstanding (in shares)	0	0
Common stock, $0.01 par value; 500,000,000 shares authorized, 206,928,325 and 205,208,018 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	500,000,000	500,000,000
Shares issued (in shares)	206,928,325	205,208,018
Shares outstanding (in shares)	206,928,325	205,208,018

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Rental and related revenues	$ 100,612	$ 110,104	$ 319,851	$ 339,291
Interest and other income	3,299	3,325	8,756	77,145
Resident fees and services	39,341	36,405	117,908	89,537
Total revenues	143,252	149,834	446,515	505,973
Expenses:
Depreciation and amortization	44,209	43,092	132,579	137,517
Interest	24,904	29,255	75,900	99,181
General and administrative	7,216	8,709	24,650	24,952
(Recovery of) provision for loan losses and other reserves	(90)	57	706	1,457
Impairment of real estate	3,154	13,966	3,154	119,102
Total expenses	112,387	124,669	335,446	459,607
Other income (expense):
Loss on extinguishment of debt	(139)	(644)	(531)	(10,763)
Other income	115	215	2,308	385
Net gain (loss) on sales of real estate	2,715	(19)	2,828	1,216
Total other income (expense)	2,691	(448)	4,605	(9,162)
Income before income (loss) from unconsolidated joint venture and income tax benefit (expense)	33,556	24,717	115,674	37,204
Income (loss) from unconsolidated joint venture	2,766	(605)	(13,037)	(5,635)
Income tax benefit (expense)	138	(826)	(1,337)	(2,292)
Net income	36,460	23,286	101,300	29,277
Net income attributable to noncontrolling interest	0	(4)	0	(22)
Net income attributable to common stockholders	$ 36,460	$ 23,282	$ 101,300	$ 29,255
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 0.18	$ 0.12	$ 0.49	$ 0.16
Diluted common share (in dollars per share)	$ 0.18	$ 0.12	$ 0.49	$ 0.16
Weighted-average number of common shares outstanding, basic (in shares)	205,791,699	190,650,400	205,592,806	183,578,254
Weighted-average number of common shares outstanding, diluted (in shares)	206,727,167	191,952,389	206,442,674	184,698,411
Revenue, Product and Service [Extensible List]	sbra:ResidentFeesAndServicesMember	sbra:ResidentFeesAndServicesMember	sbra:ResidentFeesAndServicesMember	sbra:ResidentFeesAndServicesMember
Triple-Net Portfolio
Expenses:
Operating expenses	$ 5,249	$ 5,611	$ 15,481	$ 17,140
Senior Housing - Managed
Expenses:
Operating expenses	$ 27,745	$ 23,979	$ 82,976	$ 60,258

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 36,460	$ 23,286	$ 101,300	$ 29,277
Unrealized (loss) gain, net of tax:
Foreign currency translation (loss) gain	(359)	917	814	924
Unrealized gain (loss) on cash flow hedges	6,830	(9,376)	(37,596)	(32,620)
Total other comprehensive income (loss)	6,471	(8,459)	(36,782)	(31,696)
Comprehensive income (loss)	42,931	14,827	64,518	(2,419)
Comprehensive income attributable to noncontrolling interest	0	(4)	0	(22)
Comprehensive income (loss) attributable to Sabra Health Care REIT, Inc.	$ 42,931	$ 14,823	$ 64,518	$ (2,441)

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect in Period of Adoption	Total Stockholders’ Equity	Total Stockholders’ Equity Cumulative Effect in Period of Adoption	Common Stock	Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Cumulative Distributions in Excess of Net Income Cumulative Effect in Period of Adoption	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2018					178,306,528
Beginning balance at Dec. 31, 2018	$ 3,254,747	$ (32,502)	$ 3,250,414		$ 1,783	$ 3,507,925	$ (271,595)	$ (32,502)	$ 12,301	$ 4,333
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	29,277		29,255				29,255			22
Other comprehensive income (loss)	(31,696)		(31,696)						(31,696)
Buyout of noncontrolling interest	(200)		4,039			4,039				(4,239)
Distributions to noncontrolling interest	(116)									(116)
Amortization of stock-based compensation	10,474		10,474			10,474
Common stock issuance, net (in shares)					15,390,373
Common stock issuance, net	301,300		301,300		$ 154	301,146
Common dividends	(248,867)		(248,867)				(248,867)
Ending balance (in shares) at Sep. 30, 2019					193,696,901
Ending balance at Sep. 30, 2019	$ 3,282,417		3,282,417		$ 1,937	3,823,584	(523,709)		(19,395)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201602Member
Beginning balance (in shares) at Dec. 31, 2018					178,306,528
Beginning balance at Dec. 31, 2018	$ 3,254,747	(32,502)	3,250,414		$ 1,783	3,507,925	(271,595)	(32,502)	12,301	4,333
Ending balance (in shares) at Dec. 31, 2019					205,208,018
Ending balance at Dec. 31, 2019	3,488,460	(167)	3,488,460	$ (167)	$ 2,052	4,072,079	(573,283)	(167)	(12,388)	0
Beginning balance (in shares) at Jun. 30, 2019					189,515,024
Beginning balance at Jun. 30, 2019	3,260,376		3,256,098		$ 1,895	3,725,971	(460,832)		(10,936)	4,278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	23,286		23,282				23,282			4
Other comprehensive income (loss)	(8,459)		(8,459)						(8,459)
Buyout of noncontrolling interest	(200)		4,039			4,039				(4,239)
Distributions to noncontrolling interest	(43)									(43)
Amortization of stock-based compensation	3,930		3,930			3,930
Common stock issuance, net (in shares)					4,181,877
Common stock issuance, net	89,686		89,686		$ 42	89,644
Common dividends	(86,159)		(86,159)				(86,159)
Ending balance (in shares) at Sep. 30, 2019					193,696,901
Ending balance at Sep. 30, 2019	3,282,417		3,282,417		$ 1,937	3,823,584	(523,709)		(19,395)	0
Beginning balance (in shares) at Dec. 31, 2019					205,208,018
Beginning balance at Dec. 31, 2019	3,488,460	(167)	3,488,460	(167)	$ 2,052	4,072,079	(573,283)	(167)	(12,388)	0
Ending balance (in shares) at Jun. 30, 2020					205,560,680
Ending balance at Jun. 30, 2020	3,361,251		3,361,251		$ 2,056	4,078,737	(663,901)		(55,641)	0
Beginning balance (in shares) at Dec. 31, 2019					205,208,018
Beginning balance at Dec. 31, 2019	3,488,460	$ (167)	3,488,460	$ (167)	$ 2,052	4,072,079	(573,283)	$ (167)	(12,388)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	101,300		101,300				101,300
Other comprehensive income (loss)	(36,782)		(36,782)						(36,782)
Amortization of stock-based compensation	7,582		7,582			7,582
Common stock issuance, net (in shares)					1,720,307
Common stock issuance, net	21,625		21,625		$ 17	21,608
Common dividends	(217,678)		(217,678)				(217,678)
Ending balance (in shares) at Sep. 30, 2020					206,928,325
Ending balance at Sep. 30, 2020	$ 3,364,340		3,364,340		$ 2,069	4,101,269	(689,828)		(49,170)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Beginning balance (in shares) at Jun. 30, 2020					205,560,680
Beginning balance at Jun. 30, 2020	$ 3,361,251		3,361,251		$ 2,056	4,078,737	(663,901)		(55,641)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	36,460		36,460				36,460
Other comprehensive income (loss)	6,471		6,471						6,471
Amortization of stock-based compensation	1,625		1,625			1,625
Common stock issuance, net (in shares)					1,367,645
Common stock issuance, net	20,920		20,920		$ 13	20,907
Common dividends	(62,387)		(62,387)				(62,387)
Ending balance (in shares) at Sep. 30, 2020					206,928,325
Ending balance at Sep. 30, 2020	$ 3,364,340		$ 3,364,340		$ 2,069	$ 4,101,269	$ (689,828)		$ (49,170)	$ 0

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares				3 Months Ended		9 Months Ended
	Aug. 05, 2020	May 06, 2020	Feb. 04, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]
Common dividends (in dollars per share)	$ 0.30	$ 0.30	$ 0.45	$ 0.30	$ 0.45	$ 1.05	$ 1.35

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net income	$ 36,460	$ 23,286	$ 101,300	$ 29,277
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	44,209	43,092	132,579	137,517
Non-cash rental and related revenues			1,340	(12,965)
Non-cash interest income			(1,743)	(1,680)
Non-cash interest expense	2,100	2,500	6,527	7,846
Stock-based compensation expense			5,651	8,829
Non-cash lease termination income			0	(9,725)
Loss on extinguishment of debt	139	644	531	10,763
Provision for loan losses and other reserves	(90)	57	706	1,457
Net gain on sales of real estate	(2,715)	19	(2,828)	(1,216)
Impairment of real estate	3,154	13,966	3,154	119,102
Loss from unconsolidated joint venture	(2,766)	605	13,037	5,635
Distributions of earnings from unconsolidated joint venture			11,318	10,162
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net			(3,523)	(7,252)
Accounts payable and accrued liabilities			(2,594)	(20,769)
Net cash provided by operating activities			265,455	276,981
Cash flows from investing activities:
Acquisition of real estate			(92,945)	(14,977)
Origination and fundings of loans receivable			(1,651)	(9,441)
Origination and fundings of preferred equity investments			(20,059)	0
Additions to real estate			(32,416)	(15,985)
Repayments of loans receivable			3,095	13,761
Repayments of preferred equity investments			3,399	3,672
Net proceeds from the sales of real estate			8,754	321,715
Distributions in excess of earnings from unconsolidated joint venture			1,305	0
Buyout of noncontrolling interests			0	(200)
Net cash (used in) provided by investing activities			(130,518)	298,545
Cash flows from financing activities:
Net borrowings from (repayments of) revolving credit facility			56,000	(424,000)
Proceeds from issuance of senior unsecured notes			0	297,039
Principal payments on senior unsecured notes			0	(500,000)
Principal payments on secured debt			(2,396)	(2,566)
Payments of deferred financing costs			(819)	(14,001)
Payments related to extinguishment of debt			0	(6,897)
Distributions to noncontrolling interest			0	(116)
Issuance of common stock, net			20,961	302,030
Dividends paid on common stock			(215,747)	(247,222)
Net cash used in financing activities			(142,001)	(595,733)
Net decrease in cash, cash equivalents and restricted cash			(7,064)	(20,207)
Effect of foreign currency translation on cash, cash equivalents and restricted cash			(230)	211
Cash, cash equivalents and restricted cash, beginning of period			49,143	59,658	$ 59,658
Cash, cash equivalents and restricted cash, end of period	$ 41,849	$ 39,662	41,849	39,662	$ 49,143
Supplemental disclosure of cash flow information:
Interest paid			67,995	100,230
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate			20,731	0
Secured debt assumed by buyers in connection with sales of real estate			$ 31,830	$ 0

XML

BUSINESS

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS

BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”) and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

COVID-19

In March 2020, the World Health Organization declared COVID-19 a pandemic, and the United States declared a national emergency with respect to COVID-19. In the intervening months, COVID-19 has spread globally and led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to control its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders. Although some of these governmental restrictions have since been lifted or scaled back, a recent surge of COVID-19 infections has resulted in the re-imposition of certain restrictions and may lead to other restrictions being re-implemented in response to efforts to reduce the spread of COVID-19. These measures may remain in place for a significant amount of time. The COVID-19 pandemic and measures to prevent its spread have negatively impacted and are expected to continue to negatively impact the Company and its operations in a number of ways, including but not limited to:

•Decreased occupancy and increased operating costs for the Company’s tenants and borrowers, which has negatively impacted their operating results and may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to the Company. In some cases, the Company may have to restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to the Company as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of the Company’s investments are not recoverable, which could result in an impairment charge. To date, the impact of COVID-19 on the Company’s skilled nursing/transitional care facility operators has been partially mitigated by the assistance they have received or expect to receive from state and federal assistance programs, including through the CARES Act (as defined and further described below under “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Skilled Nursing Facility Reimbursement Rates” in Part I, Item 2), although these benefits on an individual operator basis vary and may not provide enough relief to meet their rental obligations to the Company. Prior to September 1, 2020, few of these programs were available to the Company’s senior housing operators; as of September 1, 2020, eligible assisted living facility operators may apply for funding through the CARES Act, and the assistance received or expected to be received will partially mitigate the negative impact of COVID-19 on the Company’s eligible assisted living facility operators. As of September 30, 2020, the Company’s tenants and borrowers have continued to pay expected cash rents and debt service obligations consistent with past practice. However, the longer the duration of the COVID-19 pandemic, the more likely that the Company’s tenants and borrowers will begin to default on these obligations. Such defaults could materially and adversely affect the Company’s results of operations and liquidity, in addition to resulting in potential impairment charges.

•Decreased occupancy and increased operating costs within the Company’s Senior Housing - Managed portfolio and in the Company’s 49% equity interest in a joint venture with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, that owns senior housing communities managed by Enlivant (the “Enlivant Joint Venture”), which have negatively impacted and are expected to continue to negatively impact the operating results of these

investments. As noted above, as of September 1, 2020, eligible assisted living facility operators may apply for funding through the CARES Act, and the assistance received or expected to be received will partially mitigate the negative impact of COVID-19 on the Company’s Senior Housing - Managed portfolio and the Enlivant Joint Venture. During each of the three and nine months ended September 30, 2020, the Company recognized government grants under the CARES Act of $4.2 million. In addition, on October 1, 2020, the Department of Health and Human Services announced $20 billion of new funding for assisted living facility operators that have already received funds and to those who were previously ineligible. Prolonged deterioration in the operating results for the Company’s investments in its Senior Housing - Managed portfolio and the Enlivant Joint Venture could result in the determination that the full amounts of the Company’s investments are not recoverable, which could result in an impairment charge.

The Company’s financial results as of and for the three and nine months ended September 30, 2020 reflect the results of the Company’s evaluation of the impact of COVID-19 on its business including, but not limited to, its evaluation of potential impairments of long-lived or other assets, measurement of credit losses on financial instruments, evaluation of any lease modifications, evaluation of lease accounting impact, estimates of fair value and the Company’s ability to continue as a going concern.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2020 and December 31, 2019 and for the three and nine month periods ended September 30, 2020 and 2019. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2020, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the

Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2020, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of September 30, 2020, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s condensed consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.

Out of Period Adjustments

During the three months ended September 30, 2020, the Company identified certain historical errors in the recording of depreciation and amortization expense related to the basis difference in the Enlivant Joint Venture and not correctly expensing the allocable portion of the basis difference upon the sale of assets in the Enlivant Joint Venture. These errors impacted the Company’s investment in unconsolidated joint venture and income (loss) from unconsolidated joint venture as well as its condensed consolidated statements of income, condensed consolidated statements of comprehensive income (loss) and condensed consolidated statements of equity since 2018, which impacted the quarterly financial statements and annual periods previously issued. These errors resulted in understating (overstating) previously recorded income (loss) from unconsolidated joint venture and net income by $5.2 million for the six months ended June 30, 2020 and $0.1 million and ($1.7) million for the years ended December 31, 2019 and 2018, respectively. These out of period adjustments were recorded in the third quarter of 2020, resulting in an increase to income from unconsolidated joint venture and net income of $3.6 million. Management evaluated the impact of the errors to the current period and prior period financial statements and determined that the impact was not material to any of the impacted periods.

Government Grants

Government assistance provided to the Company in the form of an income grant, which is not related to long-lived assets and is not required to be repaid, is recognized as grant income when there is reasonable assurance that the grant will be received and the Company will comply with any conditions associated with the grant. Additionally, grants are recognized over the periods in which the Company recognizes the qualifying expenses and/or lost income for which the grants are intended to compensate. As of September 30, 2020, the amount of qualifying expenditures exceeded amounts recognized under the CARES Act, and the Company had complied with all grant conditions. Accordingly, during each of the three and nine months ended September 30, 2020, the Company recognized $1.2 million of grants in resident fees and services and $3.0 million of grants in loss from unconsolidated joint venture in the condensed consolidated statements of income.

Recently Issued Accounting Standards Update

Adopted

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB

issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with ASU 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 (collectively, “Topic 326”) on January 1, 2020.

The financial assets within the scope of Topic 326 are the Company’s investments in a direct financing lease and loans receivable, including the portion of unfunded loan commitments expected to be funded. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. Related interest income receivable balances are evaluated separately for collectability, and reserves are established based on management’s estimate of losses.

Upon adoption of these standards, the Company recognized the cumulative effect on the opening balance of the allowance for credit losses in the condensed consolidated balance sheets, which resulted in an increase to cumulative distributions in excess of net income and a decrease to total assets of $0.2 million.

Issued but Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2022. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

XML

RECENT REAL ESTATE ACQUISITIONS

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

RECENT REAL ESTATE ACQUISITIONS

RECENT REAL ESTATE ACQUISITIONS

During the nine months ended September 30, 2020, the Company acquired three Senior Housing - Leased communities and one Senior Housing - Managed community. These investments were part of the Company’s proprietary development pipeline, and $20.7 million was previously funded through its preferred equity investments in these developments. During the nine months ended September 30, 2019, the Company acquired two specialty hospitals/other facilities. The consideration was allocated as follows (in thousands):

	Nine Months Ended September 30,
	2020		2019
Land	$	5,800	$	2,040
Building and improvements	104,952		12,652
Tenant origination and absorption costs intangible assets	2,578		234
Tenant relationship intangible assets	347		51
Total consideration	$	113,677	$	14,977

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-

average amortization periods as of the respective dates of acquisition of seven years and 25 years, respectively, for acquisitions completed during the nine months ended September 30, 2020, and 15 years and 25 years, respectively, for acquisitions completed during the nine months ended September 30, 2019.

For the three and nine months ended September 30, 2020, the Company recognized $3.4 million and $9.2 million of total revenues, respectively, and $1.4 million and $3.7 million of net income attributable to common stockholders, respectively, from the facilities acquired during the nine months ended September 30, 2020. For each of the three and nine months ended September 30, 2019, the Company recognized $0.2 million of total revenues and $0.2 million of net income attributable to common stockholders from the facilities acquired during the nine months ended September 30, 2019.

XML

INVESTMENT IN REAL ESTATE PROPERTIES

9 Months Ended

Sep. 30, 2020

Real Estate Investments, Net [Abstract]

INVESTMENT IN REAL ESTATE PROPERTIES

INVESTMENT IN REAL ESTATE PROPERTIES

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of September 30, 2020

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	287	32,019	$	3,642,653	$	(360,742)	$	3,281,911
Senior Housing - Leased	64	4,242	707,379		(83,105)		624,274
Senior Housing - Managed	47	4,924	931,655		(134,056)		797,599
Specialty Hospitals and Other	27	1,193	663,982		(61,909)		602,073
	425	42,378	5,945,669		(639,812)		5,305,857
Corporate Level			817		(402)		415
			$	5,946,486	$	(640,214)	$	5,306,272

As of December 31, 2019

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	296	33,290	$	3,701,666	$	(306,565)	$	3,395,101
Senior Housing - Leased	62	3,820	630,688		(72,278)		558,410
Senior Housing - Managed	46	4,809	907,771		(112,893)		794,878
Specialty Hospitals and Other	25	1,193	639,721		(47,124)		592,597
	429	43,112	5,879,846		(538,860)		5,340,986
Corporate Level			737		(353)		384
			$	5,880,583	$	(539,213)	$	5,341,370

	September 30, 2020		December 31, 2019
Building and improvements	$	5,107,022	$	5,042,435
Furniture and equipment	243,265		239,229
Land improvements	1,917		1,534
Land	594,282		597,385
	5,946,486		5,880,583
Accumulated depreciation	(640,214)		(539,213)
	$	5,306,272	$	5,341,370

Operating Leases

As of September 30, 2020, the substantial majority of the Company’s real estate properties (excluding 47 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of September 30, 2020, the leases had a weighted-average remaining term of eight years. The leases generally include

provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets and totaled $11.7 million and $10.5 million as of September 30, 2020 and December 31, 2019, respectively, and letters of credit deposited with the Company totaled approximately $86 million and $83 million as of September 30, 2020 and December 31, 2019, respectively. In addition, the Company’s tenants have deposited with the Company $15.4 million and $14.3 million as of September 30, 2020 and December 31, 2019, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $5.0 million and $15.7 million during the three and nine months ended September 30, 2020, respectively, and $4.0 million and $13.0 million during the three and nine months ended September 30, 2019, respectively.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

During the three months ended September 30, 2020, the auditors for Genesis Healthcare, Inc. (“Genesis”) and subsidiaries of Signature Healthcare (“Signature”) that lease facilities from the Company each expressed substantial doubt over the respective abilities of Genesis and Signature to continue as a going concern. Accordingly, the Company concluded that its leases with Genesis and Signature should no longer be accounted for on an accrual basis and wrote off $14.3 million of non-cash rent receivable balances and lease intangibles related to these leases.

For the three and nine months ended September 30, 2020, no tenant relationship represented 10% or more of the Company’s total revenues.

As of September 30, 2020, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

October 1 through December 31, 2020	$	106,516
2021	431,202
2022	412,395
2023	402,083
2024	402,936
Thereafter	1,923,827
	$	3,678,959

Senior Housing - Managed Communities

The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The

Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.3 million and $0.7 million for the three and nine months ended September 30, 2020, respectively, and $0.2 million and $0.5 million for the three and nine months ended September 30, 2019, respectively.

Investment in Unconsolidated Joint Venture

The Company has a 49% equity interest in the Enlivant Joint Venture with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, that owns senior housing communities managed by Enlivant. During the nine months ended September 30, 2020, the Enlivant Joint Venture sold 12 senior housing communities for aggregate gross proceeds of $18.2 million, and the Company recorded an aggregate net loss on sale of real estate related to unconsolidated joint venture of $3.3 million. As of September 30, 2020, the Enlivant Joint Venture owned 158 senior housing communities, and the book value of the Company’s investment in the Enlivant Joint Venture was $293.8 million.

Net Investment in Direct Financing Lease

As of September 30, 2020, the Company had a $24.1 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the present value of total rental payments of $2.8 million, plus the estimated purchase price of $24.8 million, less the unearned lease income of $3.3 million and allowance for credit losses of $0.2 million as of September 30, 2020. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $0.7 million and $2.0 million for the three and nine months ended September 30, 2020, respectively, and $0.7 million and $2.0 million for the three and nine months ended September 30, 2019, respectively, and is reflected in interest and other income on the accompanying condensed consolidated statements of income. Upon adoption of Topic 326 on January 1, 2020 and as of the adoption date, the Company recorded a $0.2 million reduction in equity and increase to its allowance for credit losses due to the cumulative effect of the changes contemplated by Topic 326. During the three and nine months ended September 30, 2020, the Company reduced its allowance for credit losses by $1,000 and $38,000, respectively. Future minimum lease payments contractually due under the direct financing lease at September 30, 2020 were as follows: $0.6 million for the remainder of 2020, $2.3 million for 2021 and $0.1 million for 2022.

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

9 Months Ended

Sep. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

2020

Asset Held for Sale

As of September 30, 2020, the Company determined that one skilled nursing/transitional care facility with a net book value of $8.9 million met the criteria to be classified as an asset held for sale, and this balance is included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. Subsequent to September 30, 2020, the Company completed the sale of the facility for a gross sales price of $9.0 million.

Impairment of Real Estate

During the nine months ended September 30, 2020, the Company recognized a $3.2 million real estate impairment related to three senior housing communities and one skilled nursing/transitional care facility.

Dispositions

During the nine months ended September 30, 2020, the Company completed the sale of seven skilled nursing/transitional care facilities for aggregate consideration, net of closing costs, of $41.1 million. The net carrying value of the assets and liabilities of these facilities was $38.3 million, which resulted in an aggregate $2.8 million net gain on sale.

During the nine months ended September 30, 2020, the Company recognized $3.9 million of net income, which includes the $2.8 million net gain on sale, and during the nine months ended September 30, 2019, recognized $11.0 million of net loss, which includes $12.8 million of real estate impairment, in each case from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2019

Impairment of Real Estate

During the nine months ended September 30, 2019, the Company recognized a $119.1 million real estate impairment, of which $95.2 million related to the 30 Senior Care Centers facilities that the Company sold and one additional Senior Care Centers facility that the Company transitioned to another operator, and the remaining $23.9 million related to five additional skilled nursing/transitional care facilities that were subsequently sold and four senior housing communities.

Dispositions

During the nine months ended September 30, 2019, the Company completed the sale of 31 skilled nursing/transitional care facilities and seven senior housing communities for aggregate consideration, net of closing costs, of $315.0 million. The net carrying value of the assets and liabilities of these facilities was $313.8 million, which resulted in an aggregate $1.2 million net gain on sale.

During the nine months ended September 30, 2019, the Company recognized $65.1 million of net loss, which includes the $1.2 million net gain on sale and $69.1 million of real estate impairment, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS

9 Months Ended

Sep. 30, 2020

Receivables [Abstract]

LOANS RECEIVABLE AND OTHER INVESTMENTS

LOANS RECEIVABLE AND OTHER INVESTMENTS

As of September 30, 2020 and December 31, 2019, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

									September 30, 2020
Investment	Quantity as of September 30, 2020	Property Type	Principal Balance as of September 30, 2020 (1)		Book Value as of September 30, 2020		Book Value as of December 31, 2019		Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of September 30, 2020
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000	$	19,000	10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	3,343		3,353		2,487		8.0	%	7.8	%	09/30/22
Other	17	Multiple	43,973		40,010		42,147		6.8	%	6.9	%	03/01/21- 08/31/28
	19		66,316		62,363		63,634		7.8	%	7.9	%
Allowance for loan losses			—		(1,287)		(564)
			$	66,316	$	61,076	$	63,070
Other Investments:
Preferred Equity	6	Skilled Nursing / Senior Housing	42,533		42,744		44,304		11.3	%	11.3	%	N/A
Total	25		$	108,849	$	103,820	$	107,374	9.2	%	9.3	%

(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

As of September 30, 2020 and December 31, 2019, the Company had four loans receivable investments, with an aggregate principal balance of $2.2 million and $2.3 million, respectively, that were considered to have deteriorated credit quality. As of September 30, 2020 and December 31, 2019, the book value of the outstanding loans with deteriorated credit quality was $0.6 million and $0.8 million, respectively.

The following table presents changes in the accretable yield for the three and nine months ended September 30, 2020 and 2019 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Accretable yield, beginning of period	$	24	$	112	$	39	$	449
Accretion recognized in earnings	(7)		(53)		(22)		(357)
Reduction due to payoff	—		—		—		(33)
Accretable yield, end of period	$	17	$	59	$	17	$	59

During the three months ended September 30, 2020, the Company decreased its allowance for loan losses by $0.1 million, and during the nine months ended September 30, 2020, the Company increased its allowance for loan losses by $0.7 million.

As of September 30, 2020, the Company had a $1.3 million allowance for loan losses. As of September 30, 2020, two loans receivable investments with no book value were on nonaccrual status. As of September 30, 2020, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

As of December 31, 2019, the Company had no asset-specific loan loss reserve and a $0.6 million portfolio-based loan loss reserve. As of December 31, 2019, the Company did not consider any loans receivable investments to be impaired. As of December 31, 2019, two loans receivable investments with no book value were on nonaccrual status. As of December 31, 2019, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

During the three months ended September 30, 2019, the Company recorded no provision for specific loan losses, and during the nine months ended September 30, 2019, the Company recorded a $1.2 million provision for specific loan losses. During the three and nine months ended September 30, 2019, the Company increased its portfolio-based loss reserve by $0.1 million and $0.2 million, respectively.

XML

DEBT

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

DEBT

DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of September 30, 2020 (1)		Principal Balance as of December 31, 2019 (1)		Weighted Average Interest Rate at September 30, 2020 (2)		Maturity Date
Fixed Rate	$	80,124	$	114,777	3.68	%	December 2021 -  August 2051

(1)     Principal balance does not include deferred financing costs, net of $1.1 million and $1.7 million as of September 30, 2020 and December 31, 2019, respectively.

(2)     Weighted average interest rate includes private mortgage insurance.

On April 1, 2020, the Company sold two facilities that secured an aggregate $14.2 million of debt, which was assumed by the buyer of the facilities. On August 1, 2020, the Company sold one facility that secured $17.6 million of debt, which was assumed by the buyer of the facility.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	September 30, 2020 (1)		December 31, 2019 (1)
4.80% senior unsecured notes due 2024 (“2024 Notes”)	June 1, 2024	$	300,000	$	300,000
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.88% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		350,000
		$	1,250,000	$	1,250,000

(1)    Principal balance does not include premium, net of $6.7 million and deferred financing costs, net of $8.4 million as of September 30, 2020 and does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019.

The 2024 Notes and the 2029 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 4.80% and 3.90%, respectively, per annum. Interest is payable semiannually on June 1 and December 1 of each year for the 2024 Notes and on April 15 and October 15 of each year for the 2029 Notes.

The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

The obligations under the 2024 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes and 2029 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2024 Notes, 2026 Notes, 2027 Notes and 2029 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of September 30, 2020, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Agreement

On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”).

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $955.0 million in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $105.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024.

As of September 30, 2020, there was $56.0 million outstanding under the Revolving Credit Facility and $944.0 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.45% per annum for LIBOR based borrowings and 0.00% to 0.45% per

annum for borrowings at the Base Rate. As of September 30, 2020, the interest rate on the Revolving Credit Facility was 1.25%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that ranges from 0.85% to 1.65% depending on the Debt Ratings.

The Company has interest rate swaps that fix the LIBOR portion of the interest rate for $845.0 million of LIBOR-based borrowings under its U.S. dollar Term Loans at a weighted average rate of 1.24% and an interest rate swap that fixes the CDOR portion of the interest rate for $125.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 0.93%. In addition, CAD $125.0 million of the Canadian dollar Term Loan is designated as a net investment hedge. See Note 8, “Derivative and Hedging Instruments,” for further information.

The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances.

The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a minimum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of September 30, 2020, the Company was in compliance with all applicable financial covenants under the Credit Agreement.

Interest Expense

The Company incurred interest expense of $24.9 million and $75.9 million during the three and nine months ended September 30, 2020, respectively, and $29.3 million and $99.2 million during the three and nine months ended September 30, 2019, respectively. Interest expense includes non-cash interest expense of $2.1 million and $6.5 million for the three and nine months ended September 30, 2020, respectively, and $2.5 million and $7.8 million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020 and December 31, 2019, the Company had $18.1 million and $16.7 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2020 (in thousands): 

	Secured Indebtedness		Revolving Credit     Facility (1)		Term Loans		Senior Notes		Total
October 1 through December 31, 2020	$	655	$	—	$	—	$	—	$	655
2021	17,689		—		—		—		17,689
2022	2,412		—		105,000		—		107,412
2023	2,478		56,000		350,000		—		408,478
2024	2,545		—		593,538		300,000		896,083
Thereafter	54,345		—		—		950,000		1,004,345
Total Debt	80,124		56,000		1,048,538		1,250,000		2,434,662
Premium, net	—		—		—		6,740		6,740
Deferred financing costs, net	(1,149)		—		(8,853)		(8,416)		(18,418)
Total Debt, Net	$	78,975	$	56,000	$	1,039,685	$	1,248,324	$	2,422,984

(1)    Revolving Credit Facility is subject to two six-month extension options.

XML

DERIVATIVE AND HEDGING INSTRUMENTS

9 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE AND HEDGING INSTRUMENTS

DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. In May 2019, the Company terminated three forward starting interest rate swaps, resulting in a payment to counterparties totaling $12.6 million. The balance of the loss in other comprehensive income will be reclassified to earnings through 2029. As of September 30, 2020, approximately $12.5 million of losses, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):

	September 30, 2020		December 31, 2019
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	1,340,000	$	1,490,000
Denominated in Canadian Dollars (2)	$	250,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	53,239	$	54,489
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	3,061	$	1,811

(1) Balance includes swaps with an aggregate notional value of $400.0 million, which accretes to $600.0 million in January 2023, and two forward starting interest rate swaps and one forward starting interest rate collar with an effective date of January 2021. The forward starting interest rate swaps and forward starting interest rate collar have an aggregate notional amount of $245.0 million. Balance as of September 30, 2020 also includes six forward starting interest rate swaps with an effective date of May 2024 and an aggregate notional amount of $250.0 million.

(2)    Balance as of September 30, 2020 includes two forward starting interest rate swaps with an effective date of January 2021 and an aggregate notional amount of CAD $125.0 million.

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2020 and December 31, 2019 (dollars in thousands):    

		Count as of September 30, 2020	Fair Value				Maturity Dates
Type	Designation		September 30, 2020		December 31, 2019			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	—	$	—	$	4,239	N/A	Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swaps	Cash flow	6	3,840		—		2034	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	4,633		3,238		2025	Accounts receivable, prepaid expenses and other assets, net
			$	8,473	$	7,477
Liabilities:
Interest rate swaps	Cash flow	11	$	28,494	$	—	2021- 2024	Accounts payable and accrued liabilities
Forward starting interest rate swaps	Cash flow	4	10,742		494		2024	Accounts payable and accrued liabilities
Forward starting interest rate collars	Cash flow	1	902		132		2024	Accounts payable and accrued liabilities
CAD term loan	Net investment	1	93,538		96,025		2024	Term loans, net
			$	133,676	$	96,651

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and nine months ended September 30, 2020 and 2019 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income (Loss)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019		Income Statement Location
Cash Flow Hedges:
Interest rate products	$	3,836	$	(8,196)	$	(42,826)	$	(27,933)	Interest expense
Net Investment Hedges:
Foreign currency products	(1,044)		1,273		1,544		(3)		N/A
CAD term loan	(1,913)		1,088		2,488		(2,700)		N/A
	$	879	$	(5,835)	$	(38,794)	$	(30,636)

	(Loss) Gain Reclassified from Accumulated Other Comprehensive Income (Loss) into Income
	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019		Income Statement Location
Cash Flow Hedges:
Interest rate products	$	(2,985)	$	1,173	$	(5,148)	$	4,781	Interest expense

During the three and nine months ended September 30, 2020 and 2019, no cash flow hedges were determined to be ineffective.

Derivatives Not Designated as Hedging Instruments

As of September 30, 2020, the Company had one outstanding cross currency interest rate swap, of which a portion was not designated as a hedging instrument, in an asset position with a fair value of $0.3 million and included this amount in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. During the three and nine months ended September 30, 2020, the Company recorded $0.1 million of other expense and $13,000 of other income, respectively, related to this portion of the derivative not designated as a hedging instrument. During the three and nine months

ended September 30, 2019, the Company recorded $38,000 and $31,000, respectively, of other income related to a portion of a cross currency interest rate swap not designated as a hedging instrument.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2020 and December 31, 2019 (in thousands):

	As of September 30, 2020
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	8,473	$	—	$	8,473	$	(7,405)	$	—	$	1,068
Offsetting Liabilities:
Derivatives	$	40,138	$	—	$	40,138	$	(7,405)	$	—	$	32,733

	As of December 31, 2019
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544)	$	—	$	82

Credit Risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of September 30, 2020, the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $34.3 million. As of September 30, 2020, the Company has not posted any collateral related to these agreements. If the Company had breached any of these provisions at September 30, 2020, it could have been required to settle its obligations under the agreements at their termination value of $32.7 million.

XML

FAIR VALUE DISCLOSURES

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit

enhancements as applicable. The Company utilized discount rates ranging from 6% to 16% with a weighted average rate of 12% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized rates ranging from 2% to 3% with a weighted average rate of 3% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2020 and December 31, 2019 whose carrying amounts do not approximate their fair value (in thousands):

	September 30, 2020						December 31, 2019
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	66,316	$	61,076	$	56,956	$	67,527	$	63,070	$	59,832
Preferred equity investments	42,533		42,744		43,039		43,893		44,304		44,493
Financial liabilities:
Senior Notes	1,250,000		1,248,324		1,311,354		1,250,000		1,248,773		1,328,714
Secured indebtedness	80,124		78,975		79,249		114,777		113,070		105,510

(1)    Face value represents amounts contractually due under the terms of the respective agreements.

(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of September 30, 2020 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Financial assets:
Loans receivable	$	56,956	$	—	$	—	$	56,956
Preferred equity investments	43,039		—		—		43,039
Financial liabilities:
Senior Notes	1,311,354		—		1,311,354		—
Secured indebtedness	79,249		—		—		79,249

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the nine months ended September 30, 2020, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Recurring Basis:
Financial assets:
Forward starting interest rate swaps	$	3,840	$	—	$	3,840	$	—
Cross currency interest rate swaps	4,633		—		4,633		—
Financial liabilities:
Interest rate swaps	28,494		—		28,494		—
Forward starting interest rate swaps	10,742		—		10,742		—
Forward starting interest rate collars	902		—		902		—

XML

EQUITY

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

EQUITY

EQUITY

Common Stock

On December 11, 2019, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement.

During the three months ended September 30, 2020, the Company sold 1.4 million shares under the ATM Program at an average price of $15.70 per share, generating gross proceeds of $21.4 million, before $0.3 million of commissions. During the nine months ended September 30, 2020, the Company sold 1.6 million shares under the ATM Program at an average price of

$16.26 per share, generating gross proceeds of $25.3 million, before $0.4 million of commissions. As of September 30, 2020, the Company has not utilized the forward feature of the ATM Program and had $314.7 million available under the ATM Program.

The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2020:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 4, 2020	February 14, 2020	$	0.45	February 28, 2020
May 6, 2020	May 18, 2020	$	0.30	May 29, 2020
August 5, 2020	August 17, 2020	$	0.30	August 31, 2020

During the nine months ended September 30, 2020, the Company issued 164,224 shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares to employees as a result of restricted stock unit vestings, the employees’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the nine months ended September 30, 2020 and 2019, the Company incurred $0.9 million and $1.3 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive Loss

The following is a summary of the Company’s accumulated other comprehensive loss (in thousands):

	September 30, 2020		December 31, 2019
Foreign currency translation loss	$	(702)	$	(1,516)
Unrealized loss on cash flow hedges	(48,468)		(10,872)
Total accumulated other comprehensive loss	$	(49,170)	$	(12,388)

XML

EARNINGS PER COMMON SHARE

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2020 and 2019 (in thousands, except share and per share amounts):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Numerator
Net income attributable to common stockholders	$	36,460	$	23,282	$	101,300	$	29,255
Denominator
Basic weighted average common shares and common equivalents	205,791,699		190,650,400		205,592,806		183,578,254
Dilutive restricted stock units	935,468		1,301,989		849,868		1,120,157
Diluted weighted average common shares	206,727,167		191,952,389		206,442,674		184,698,411
Net income attributable to common stockholders, per:
Basic common share	$	0.18	$	0.12	$	0.49	$	0.16
Diluted common share	$	0.18	$	0.12	$	0.49	$	0.16

During the three and nine months ended September 30, 2020, approximately 99,700 and 113,300 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three months ended September 30, 2019, no restricted stock units were considered anti-dilutive, and during the nine months ended September 30, 2019, approximately 430 restricted stock units were not included in computing diluted earnings per share because they were considered anti-dilutive.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of September 30, 2020, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.

Dividend Declaration

On November 5, 2020, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2020 to common stockholders of record as of the close of business on November 16, 2020.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Accounting

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of September 30, 2020 and December 31, 2019 and for the three and nine month periods ended September 30, 2020 and 2019. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC.

Variable Interest Entities

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of September 30, 2020, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the

Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At September 30, 2020, none of the Company’s investments in loans were accounted for as real estate joint ventures.As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s condensed consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.

Government Grants

Government assistance provided to the Company in the form of an income grant, which is not related to long-lived assets and is not required to be repaid, is recognized as grant income when there is reasonable assurance that the grant will be received and the Company will comply with any conditions associated with the grant. Additionally, grants are recognized over the periods in which the Company recognizes the qualifying expenses and/or lost income for which the grants are intended to compensate.

Recently Issued Accounting Standards Update

Adopted

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB

issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with ASU 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 (collectively, “Topic 326”) on January 1, 2020.

The financial assets within the scope of Topic 326 are the Company’s investments in a direct financing lease and loans receivable, including the portion of unfunded loan commitments expected to be funded. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. Related interest income receivable balances are evaluated separately for collectability, and reserves are established based on management’s estimate of losses.

Upon adoption of these standards, the Company recognized the cumulative effect on the opening balance of the allowance for credit losses in the condensed consolidated balance sheets, which resulted in an increase to cumulative distributions in excess of net income and a decrease to total assets of $0.2 million.

Issued but Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2022. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Fair Value of Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit

enhancements as applicable. The Company utilized discount rates ranging from 6% to 16% with a weighted average rate of 12% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized rates ranging from 2% to 3% with a weighted average rate of 3% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

XML

RECENT REAL ESTATE ACQUISITIONS (Tables)

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Purchase Price Allocation

The consideration was allocated as follows (in thousands):

	Nine Months Ended September 30,
	2020		2019
Land	$	5,800	$	2,040
Building and improvements	104,952		12,652
Tenant origination and absorption costs intangible assets	2,578		234
Tenant relationship intangible assets	347		51
Total consideration	$	113,677	$	14,977

XML

INVESTMENT IN REAL ESTATE PROPERTIES (Tables)

9 Months Ended

Sep. 30, 2020

Real Estate Investments, Net [Abstract]

Real Estate Properties Held for Investment

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of September 30, 2020

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	287	32,019	$	3,642,653	$	(360,742)	$	3,281,911
Senior Housing - Leased	64	4,242	707,379		(83,105)		624,274
Senior Housing - Managed	47	4,924	931,655		(134,056)		797,599
Specialty Hospitals and Other	27	1,193	663,982		(61,909)		602,073
	425	42,378	5,945,669		(639,812)		5,305,857
Corporate Level			817		(402)		415
			$	5,946,486	$	(640,214)	$	5,306,272

As of December 31, 2019

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	296	33,290	$	3,701,666	$	(306,565)	$	3,395,101
Senior Housing - Leased	62	3,820	630,688		(72,278)		558,410
Senior Housing - Managed	46	4,809	907,771		(112,893)		794,878
Specialty Hospitals and Other	25	1,193	639,721		(47,124)		592,597
	429	43,112	5,879,846		(538,860)		5,340,986
Corporate Level			737		(353)		384
			$	5,880,583	$	(539,213)	$	5,341,370

	September 30, 2020		December 31, 2019
Building and improvements	$	5,107,022	$	5,042,435
Furniture and equipment	243,265		239,229
Land improvements	1,917		1,534
Land	594,282		597,385
	5,946,486		5,880,583
Accumulated depreciation	(640,214)		(539,213)
	$	5,306,272	$	5,341,370

Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases

As of September 30, 2020, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

October 1 through December 31, 2020	$	106,516
2021	431,202
2022	412,395
2023	402,083
2024	402,936
Thereafter	1,923,827
	$	3,678,959

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2020

Receivables [Abstract]

Loans Receivable and Other Investments

As of September 30, 2020 and December 31, 2019, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

									September 30, 2020
Investment	Quantity as of September 30, 2020	Property Type	Principal Balance as of September 30, 2020 (1)		Book Value as of September 30, 2020		Book Value as of December 31, 2019		Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of September 30, 2020
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000	$	19,000	10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	3,343		3,353		2,487		8.0	%	7.8	%	09/30/22
Other	17	Multiple	43,973		40,010		42,147		6.8	%	6.9	%	03/01/21- 08/31/28
	19		66,316		62,363		63,634		7.8	%	7.9	%
Allowance for loan losses			—		(1,287)		(564)
			$	66,316	$	61,076	$	63,070
Other Investments:
Preferred Equity	6	Skilled Nursing / Senior Housing	42,533		42,744		44,304		11.3	%	11.3	%	N/A
Total	25		$	108,849	$	103,820	$	107,374	9.2	%	9.3	%

(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

Changes in Accretable Yield of Loans with Deteriorated Credit Quality

The following table presents changes in the accretable yield for the three and nine months ended September 30, 2020 and 2019 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Accretable yield, beginning of period	$	24	$	112	$	39	$	449
Accretion recognized in earnings	(7)		(53)		(22)		(357)
Reduction due to payoff	—		—		—		(33)
Accretable yield, end of period	$	17	$	59	$	17	$	59

XML

DEBT (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of September 30, 2020 (1)		Principal Balance as of December 31, 2019 (1)		Weighted Average Interest Rate at September 30, 2020 (2)		Maturity Date
Fixed Rate	$	80,124	$	114,777	3.68	%	December 2021 -  August 2051

(1)     Principal balance does not include deferred financing costs, net of $1.1 million and $1.7 million as of September 30, 2020 and December 31, 2019, respectively.

(2)     Weighted average interest rate includes private mortgage insurance.

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	September 30, 2020 (1)		December 31, 2019 (1)
4.80% senior unsecured notes due 2024 (“2024 Notes”)	June 1, 2024	$	300,000	$	300,000
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.88% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		350,000
		$	1,250,000	$	1,250,000

(1)    Principal balance does not include premium, net of $6.7 million and deferred financing costs, net of $8.4 million as of September 30, 2020 and does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019.

Schedule of Maturities for Outstanding Debt

The following is a schedule of maturities for the Company’s outstanding debt as of September 30, 2020 (in thousands): 

	Secured Indebtedness		Revolving Credit     Facility (1)		Term Loans		Senior Notes		Total
October 1 through December 31, 2020	$	655	$	—	$	—	$	—	$	655
2021	17,689		—		—		—		17,689
2022	2,412		—		105,000		—		107,412
2023	2,478		56,000		350,000		—		408,478
2024	2,545		—		593,538		300,000		896,083
Thereafter	54,345		—		—		950,000		1,004,345
Total Debt	80,124		56,000		1,048,538		1,250,000		2,434,662
Premium, net	—		—		—		6,740		6,740
Deferred financing costs, net	(1,149)		—		(8,853)		(8,416)		(18,418)
Total Debt, Net	$	78,975	$	56,000	$	1,039,685	$	1,248,324	$	2,422,984

(1)    Revolving Credit Facility is subject to two six-month extension options.

XML

DERIVATIVE AND HEDGING INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Notional Amount of Derivatives Instruments

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):

	September 30, 2020		December 31, 2019
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	1,340,000	$	1,490,000
Denominated in Canadian Dollars (2)	$	250,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	53,239	$	54,489
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	3,061	$	1,811

(1) Balance includes swaps with an aggregate notional value of $400.0 million, which accretes to $600.0 million in January 2023, and two forward starting interest rate swaps and one forward starting interest rate collar with an effective date of January 2021. The forward starting interest rate swaps and forward starting interest rate collar have an aggregate notional amount of $245.0 million. Balance as of September 30, 2020 also includes six forward starting interest rate swaps with an effective date of May 2024 and an aggregate notional amount of $250.0 million.

(2)    Balance as of September 30, 2020 includes two forward starting interest rate swaps with an effective date of January 2021 and an aggregate notional amount of CAD $125.0 million.

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at September 30, 2020 and December 31, 2019 (dollars in thousands):    

		Count as of September 30, 2020	Fair Value				Maturity Dates
Type	Designation		September 30, 2020		December 31, 2019			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	—	$	—	$	4,239	N/A	Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swaps	Cash flow	6	3,840		—		2034	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	4,633		3,238		2025	Accounts receivable, prepaid expenses and other assets, net
			$	8,473	$	7,477
Liabilities:
Interest rate swaps	Cash flow	11	$	28,494	$	—	2021- 2024	Accounts payable and accrued liabilities
Forward starting interest rate swaps	Cash flow	4	10,742		494		2024	Accounts payable and accrued liabilities
Forward starting interest rate collars	Cash flow	1	902		132		2024	Accounts payable and accrued liabilities
CAD term loan	Net investment	1	93,538		96,025		2024	Term loans, net
			$	133,676	$	96,651

Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and nine months ended September 30, 2020 and 2019 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income (Loss)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019		Income Statement Location
Cash Flow Hedges:
Interest rate products	$	3,836	$	(8,196)	$	(42,826)	$	(27,933)	Interest expense
Net Investment Hedges:
Foreign currency products	(1,044)		1,273		1,544		(3)		N/A
CAD term loan	(1,913)		1,088		2,488		(2,700)		N/A
	$	879	$	(5,835)	$	(38,794)	$	(30,636)

	(Loss) Gain Reclassified from Accumulated Other Comprehensive Income (Loss) into Income
	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019		Income Statement Location
Cash Flow Hedges:
Interest rate products	$	(2,985)	$	1,173	$	(5,148)	$	4,781	Interest expense

Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2020 and December 31, 2019 (in thousands):

	As of September 30, 2020
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	8,473	$	—	$	8,473	$	(7,405)	$	—	$	1,068
Offsetting Liabilities:
Derivatives	$	40,138	$	—	$	40,138	$	(7,405)	$	—	$	32,733

	As of December 31, 2019
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544)	$	—	$	82

Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of September 30, 2020 and December 31, 2019 (in thousands):

	As of September 30, 2020
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	8,473	$	—	$	8,473	$	(7,405)	$	—	$	1,068
Offsetting Liabilities:
Derivatives	$	40,138	$	—	$	40,138	$	(7,405)	$	—	$	32,733

	As of December 31, 2019
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544)	$	—	$	82

XML

FAIR VALUE DISCLOSURES (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Face Values, Carrying Amounts and Fair Values of Financial Instruments

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of September 30, 2020 and December 31, 2019 whose carrying amounts do not approximate their fair value (in thousands):

	September 30, 2020						December 31, 2019
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	66,316	$	61,076	$	56,956	$	67,527	$	63,070	$	59,832
Preferred equity investments	42,533		42,744		43,039		43,893		44,304		44,493
Financial liabilities:
Senior Notes	1,250,000		1,248,324		1,311,354		1,250,000		1,248,773		1,328,714
Secured indebtedness	80,124		78,975		79,249		114,777		113,070		105,510

(1)    Face value represents amounts contractually due under the terms of the respective agreements.

(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

Fair Value of Financial Instruments

The Company determined the fair value of financial instruments as of September 30, 2020 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Financial assets:
Loans receivable	$	56,956	$	—	$	—	$	56,956
Preferred equity investments	43,039		—		—		43,039
Financial liabilities:
Senior Notes	1,311,354		—		1,311,354		—
Secured indebtedness	79,249		—		—		79,249

Items Measured at Fair Value on a Recurring Basis

During the nine months ended September 30, 2020, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Recurring Basis:
Financial assets:
Forward starting interest rate swaps	$	3,840	$	—	$	3,840	$	—
Cross currency interest rate swaps	4,633		—		4,633		—
Financial liabilities:
Interest rate swaps	28,494		—		28,494		—
Forward starting interest rate swaps	10,742		—		10,742		—
Forward starting interest rate collars	902		—		902		—

XML

EQUITY (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Cash Dividends on Common Stock Declared and Paid

The following table lists the cash dividends on common stock declared and paid by the Company during the nine months ended September 30, 2020:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 4, 2020	February 14, 2020	$	0.45	February 28, 2020
May 6, 2020	May 18, 2020	$	0.30	May 29, 2020
August 5, 2020	August 17, 2020	$	0.30	August 31, 2020

Accumulated Other Comprehensive (Loss) Income

The following is a summary of the Company’s accumulated other comprehensive loss (in thousands):

	September 30, 2020		December 31, 2019
Foreign currency translation loss	$	(702)	$	(1,516)
Unrealized loss on cash flow hedges	(48,468)		(10,872)
Total accumulated other comprehensive loss	$	(49,170)	$	(12,388)

XML

EARNINGS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table illustrates the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2020 and 2019 (in thousands, except share and per share amounts):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Numerator
Net income attributable to common stockholders	$	36,460	$	23,282	$	101,300	$	29,255
Denominator
Basic weighted average common shares and common equivalents	205,791,699		190,650,400		205,592,806		183,578,254
Dilutive restricted stock units	935,468		1,301,989		849,868		1,120,157
Diluted weighted average common shares	206,727,167		191,952,389		206,442,674		184,698,411
Net income attributable to common stockholders, per:
Basic common share	$	0.18	$	0.12	$	0.49	$	0.16
Diluted common share	$	0.18	$	0.12	$	0.49	$	0.16

XML

BUSINESS (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Jan. 02, 2018
Schedule of Equity Method Investments [Line Items]
Government grants received under the CARES Act	$ 4.2	$ 4.2
Enlivant Joint Venture
Schedule of Equity Method Investments [Line Items]
Equity interest in joint venture	49.00%	49.00%	49.00%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended		30 Months Ended
	Sep. 30, 2020 USD ($) variableInterestEntity investment	Sep. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Sep. 30, 2020 USD ($) variableInterestEntity investment	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Jun. 30, 2020 USD ($)	Jan. 01, 2020 USD ($)	Jun. 30, 2019 USD ($)
Accounting Policies [Line Items]
Number of investments in loans accounted for as real estate joint ventures | investment	0			0
Net income	$ 36,460	$ 23,286		$ 101,300	$ 29,277
Income (loss) from unconsolidated joint venture	2,766	(605)		$ (13,037)	$ (5,635)
Accounting Standards Update [Extensible List]				us-gaap:AccountingStandardsUpdate201613Member	us-gaap:AccountingStandardsUpdate201602Member
Cumulative effect of ASU adoption	3,364,340	3,282,417	$ 3,361,251	$ 3,364,340	$ 3,282,417	$ 3,488,460	$ 3,254,747	$ 3,361,251		$ 3,260,376
Total assets	(5,991,618)			(5,991,618)		(6,069,299)
Resident Fee and Services Fee
Accounting Policies [Line Items]
Grant income	1,200			1,200
Loss from Unconsolidated Joint Venture
Accounting Policies [Line Items]
Grant income	3,000			3,000
Out of Period Adjustment | Correction of Depreciation and Amortization Expense
Accounting Policies [Line Items]
Net income			5,200			100	(1,700)	3,600
Income (loss) from unconsolidated joint venture			5,200			100	(1,700)	3,600
Cumulative Distributions in Excess of Net Income
Accounting Policies [Line Items]
Net income	36,460	23,282		101,300	29,255
Cumulative effect of ASU adoption	$ (689,828)	$ (523,709)	$ (663,901)	$ (689,828)	$ (523,709)	(573,283)	(271,595)	$ (663,901)		$ (460,832)
Primary Beneficiary
Accounting Policies [Line Items]
Number of variable interest entities | variableInterestEntity	0			0
Cumulative Effect in Period of Adoption
Accounting Policies [Line Items]
Cumulative effect of ASU adoption						(167)	(32,502)
Total assets									$ 200
Cumulative Effect in Period of Adoption | Cumulative Distributions in Excess of Net Income
Accounting Policies [Line Items]
Cumulative effect of ASU adoption						$ (167)	$ (32,502)		$ 200

XML

RECENT REAL ESTATE ACQUISITIONS - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) property	Sep. 30, 2019 USD ($) property
Business Acquisition [Line Items]
Number of acquired properties | property				2
Recent Real Estate Acquisitions
Business Acquisition [Line Items]
Total revenues | $	$ 3.4	$ 0.2	$ 9.2	$ 0.2
Net income attributable to common stockholders | $	$ 1.4	$ 0.2	$ 3.7	$ 0.2
Recent Real Estate Acquisitions | Tenant Origination and Absorption Costs
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets			7 years	15 years
Recent Real Estate Acquisitions | Tenant Relationship
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets			25 years	25 years
Recent Real Estate Acquisitions | Senior Housing Facilities
Business Acquisition [Line Items]
Amount previously funded through preferred equity investments | $			$ 20.7
Recent Real Estate Acquisitions | Senior Housing - Leased
Business Acquisition [Line Items]
Number of acquired properties | property			3
Recent Real Estate Acquisitions | Senior Housing - Managed
Business Acquisition [Line Items]
Number of acquired properties | property			1

XML

RECENT REAL ESTATE ACQUISITIONS - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Land	$ 5,800	$ 2,040
Building and improvements	104,952	12,652
Total consideration	113,677	14,977
Tenant origination and absorption costs intangible assets
Business Acquisition [Line Items]
Tenant intangible assets	2,578	234
Tenant relationship intangible assets
Business Acquisition [Line Items]
Tenant intangible assets	$ 347	$ 51

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) $ in Thousands	Sep. 30, 2020 USD ($) bed facility	Dec. 31, 2019 USD ($) bed facility
Real Estate Properties [Line Items]
Building and improvements	$ 5,107,022	$ 5,042,435
Furniture and equipment	243,265	239,229
Land improvements	1,917	1,534
Land	594,282	597,385
Total Real Estate at Cost	5,946,486	5,880,583
Accumulated Depreciation	(640,214)	(539,213)
Total Real Estate Investments, Net	$ 5,306,272	$ 5,341,370
Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	425	429
Number of Beds/Units | bed	42,378	43,112
Total Real Estate at Cost	$ 5,945,669	$ 5,879,846
Accumulated Depreciation	(639,812)	(538,860)
Total Real Estate Investments, Net	$ 5,305,857	5,340,986
Operating Segments | Senior Housing - Managed
Real Estate Properties [Line Items]
Number of Properties | facility	47
Corporate Level
Real Estate Properties [Line Items]
Total Real Estate at Cost	$ 817	737
Accumulated Depreciation	(402)	(353)
Total Real Estate Investments, Net	$ 415	$ 384
Skilled Nursing/Transitional Care | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	287	296
Number of Beds/Units | bed	32,019	33,290
Total Real Estate at Cost	$ 3,642,653	$ 3,701,666
Accumulated Depreciation	(360,742)	(306,565)
Total Real Estate Investments, Net	$ 3,281,911	$ 3,395,101
Senior Housing - Leased | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	64	62
Number of Beds/Units | bed	4,242	3,820
Total Real Estate at Cost	$ 707,379	$ 630,688
Accumulated Depreciation	(83,105)	(72,278)
Total Real Estate Investments, Net	$ 624,274	$ 558,410
Senior Housing - Managed | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	47	46
Number of Beds/Units | bed	4,924	4,809
Total Real Estate at Cost	$ 931,655	$ 907,771
Accumulated Depreciation	(134,056)	(112,893)
Total Real Estate Investments, Net	$ 797,599	$ 794,878
Specialty Hospitals and Other | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	27	25
Number of Beds/Units | bed	1,193	1,193
Total Real Estate at Cost	$ 663,982	$ 639,721
Accumulated Depreciation	(61,909)	(47,124)
Total Real Estate Investments, Net	$ 602,073	$ 592,597

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($) facility	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) facility	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) facility
Real Estate Properties [Line Items]
Weighted-average remaining term of operating leases	8 years		8 years
Security deposit liability	$ 11.7		$ 11.7		$ 10.5
Letters of credit deposited	86.0		86.0		83.0
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements	15.4		15.4		$ 14.3
Variable lease revenue	5.0	$ 4.0	$ 15.7	$ 13.0
Write off of non-cash rent receivable balances and lease intangibles	$ 14.3
Minimum
Real Estate Properties [Line Items]
Operating lease expiration term	1 year		1 year
Maximum
Real Estate Properties [Line Items]
Operating lease expiration term	15 years		15 years
Operating Segments
Real Estate Properties [Line Items]
Number of properties | facility	425		425		429
Senior Housing - Managed Communities | Operating Segments
Real Estate Properties [Line Items]
Number of properties | facility	47		47

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2020 USD ($)
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:
October 1 through December 31, 2020	$ 106,516
2021	431,202
2022	412,395
2023	402,083
2024	402,936
Thereafter	1,923,827
Total	$ 3,678,959

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Real Estate [Line Items]
Resident fees and services	$ 39,341	$ 36,405	$ 117,908	$ 89,537
Ancillary Services
Real Estate [Line Items]
Resident fees and services	$ 300	$ 200	$ 700	$ 500

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($) property	Dec. 31, 2019 USD ($)	Jan. 02, 2018
Real Estate [Line Items]
Investment in unconsolidated joint venture	$ 293,801	$ 319,460
Enlivant Joint Venture
Real Estate [Line Items]
Equity interest in joint venture	49.00%		49.00%
Investment in unconsolidated joint venture	$ 293,800
Senior Housing Facilities | Enlivant Joint Venture
Real Estate [Line Items]
Aggregate net loss on sale of real estate	$ 3,300
Senior Housing Facilities | Enlivant Joint Venture
Real Estate [Line Items]
Number of real estate properties sold | property	12
Aggregate gross proceeds from the sale of real estate	$ 18,200
Number of properties | property	158

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Direct Financing Lease (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($) property	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) property	Sep. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jan. 01, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)
Real Estate [Line Items]
Accounting Standards Update [Extensible List]			us-gaap:AccountingStandardsUpdate201613Member	us-gaap:AccountingStandardsUpdate201602Member
Cumulative effect of ASU adoption	$ 3,364,340	$ 3,282,417	$ 3,364,340	$ 3,282,417	$ 3,361,251		$ 3,488,460	$ 3,260,376	$ 3,254,747
Direct Financing Lease, Income, Comprehensive Income [Extensible List]		us-gaap:InterestAndFeeIncomeLoansAndLeases		us-gaap:InterestAndFeeIncomeLoansAndLeases
Skilled Nursing Transitional Care Facilities
Real Estate [Line Items]
Net investment in direct financing lease	$ 24,100		$ 24,100
Number of properties in direct financing lease | property	1		1
Undiscounted rental payments	$ 2,800		$ 2,800
Estimated purchase price	24,800		24,800
Unearned lease income	3,300		3,300
Allowance for credit losses related to direct financing lease	200		200
Lease income	700	$ 700	2,000	$ 2,000
Reduction in the allowance for credit losses related to direct financing lease	1		38
Future minimum lease payments contractually due under the direct financing lease for the remainder of this year	600		600
Future minimum lease payments contractually due under the direct financing lease due for next year	2,300		2,300
Future minimum lease payments contractually due under the direct financing lease due for year two	$ 100		$ 100
Cumulative Effect in Period of Adoption
Real Estate [Line Items]
Cumulative effect of ASU adoption							$ (167)		$ (32,502)
Cumulative Effect in Period of Adoption | Skilled Nursing Transitional Care Facilities | Direct Financing Lease
Real Estate [Line Items]
Cumulative effect of ASU adoption						$ (200)

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($) facility	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) facility	Sep. 30, 2019 USD ($) facility	Nov. 05, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment	$ 3,154	$ 13,966	$ 3,154	$ 119,102
Skilled Nursing/Transitional Care Facilities and Senior Housing Communities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment				$ 23,900
Skilled Nursing Transitional Care Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties held for sale | facility	1		1
Net book value of properties held for sale	$ 8,900		$ 8,900
Number of real estate properties impaired | facility			1	5
Senior Housing Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility			3	4
Senior Care Centers Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment				$ 95,200
Senior Care Centers Facilities - Subsequently Sold
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility				30
Senior Care Centers Facilities - Not Subsequently Sold
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility				1
2020 Dispositions | Skilled Nursing Transitional Care Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility			7
Aggregate sale price of facility	41,100		$ 41,100
Carrying value of assets and liabilities of facility	$ 38,300		38,300
Net gain (loss) on sale			2,800
Net income (loss) from facilities			$ 3,900	$ (11,000)
Real estate impairment				12,800
2020 Dispositions | Skilled Nursing Transitional Care Facilities | Dispositions | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate sale price of facility					$ 9,000
2019 Dispositions | Skilled Nursing/Transitional Care Facilities and Senior Housing Communities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate sale price of facility		315,000		315,000
Carrying value of assets and liabilities of facility		$ 313,800		313,800
Net gain (loss) on sale				1,200
Real estate impairment				69,100
Net income (loss) from facilities sold				$ (65,100)
2019 Dispositions | Skilled Nursing Transitional Care Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility				31
2019 Dispositions | Senior Housing Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility				7

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) $ in Thousands	Sep. 30, 2020 USD ($) investment preferredEquityInvestment loan	Dec. 31, 2019 USD ($)
Loans Receivable:
Quantity | loan	19
Principal balance	$ 66,316	$ 67,527
Book Value	62,363	63,634
Allowance for loan losses	(1,287)	(564)
Book Value	$ 61,076	63,070
Weighted Average Contractual Interest Rate / Rate of Return	7.80%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.90%
Other Investments:
Quantity | preferredEquityInvestment	6
Principal Balance	$ 42,533	43,893
Book Value	$ 42,744	44,304
Weighted Average Contractual Interest Rate / Rate of Return	11.30%
Weighted Average Annualized Effective Interest Rate / Rate of Return	11.30%
Total Quantity | investment	25
Total Principal Balance	$ 108,849
Total Book Value	$ 103,820	107,374
Total Weighted Average Contractual Interest Rate / Rate of Return	9.20%
Total Weighted Average Annualized Effective Interest Rate / Rate of Return	9.30%
Mortgage
Loans Receivable:
Quantity | loan	1
Principal balance	$ 19,000
Book Value	$ 19,000	19,000
Weighted Average Contractual Interest Rate / Rate of Return	10.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	10.00%
Construction
Loans Receivable:
Quantity | loan	1
Principal balance	$ 3,343
Book Value	$ 3,353	2,487
Weighted Average Contractual Interest Rate / Rate of Return	8.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.80%
Other
Loans Receivable:
Quantity | loan	17
Principal balance	$ 43,973
Book Value	$ 40,010	$ 42,147
Weighted Average Contractual Interest Rate / Rate of Return	6.80%
Weighted Average Annualized Effective Interest Rate / Rate of Return	6.90%

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($) loan	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) loan	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) loan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Principal balance	$ 66,316,000		$ 66,316,000		$ 67,527,000
Book value	62,363,000		62,363,000		63,634,000
Increase (decrease) in the allowance for loan losses	(100,000)	$ 100,000	700,000	$ 200,000
Allowance for loan losses	$ 1,287,000		$ 1,287,000		$ 564,000
Nonperforming Financial Instruments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable considered to be impaired | loan					0
Number of loans receivable on nonaccrual status | loan	2		2		2
Book value of loans receivable on nonaccrual status	$ 0		$ 0		$ 0
Portfolio-Based Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Increase (decrease) in the allowance for loan losses		200,000
Allowance for loan losses					600,000
Specific Loans | Nonperforming Financial Instruments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for loan losses					$ 0
Provision recorded for specific loan losses		$ 0		$ 1,200,000
Receivables Acquired with Deteriorated Credit Quality
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable considered to be impaired | loan	4		4		4
Principal balance	$ 2,200,000		$ 2,200,000		$ 2,300,000
Book value	$ 600,000		$ 600,000		$ 800,000

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Changes in the Accretable Yield (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Accretable Yield Movement Schedule [Roll Forward]
Accretable yield, beginning of period	$ 24	$ 112	$ 39	$ 449
Accretion recognized in earnings	(7)	(53)	(22)	(357)
Reduction due to payoff	0	0	0	(33)
Accretable yield, end of period	$ 17	$ 59	$ 17	$ 59

XML

DEBT - Secured Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Deferred financing costs, net	$ 18,418
Secured Debt
Debt Instrument [Line Items]
Deferred financing costs, net	1,149	$ 1,700
Secured Debt | Fixed Rate
Debt Instrument [Line Items]
Principal balance	$ 80,124	$ 114,777
Weighted average interest rate	3.68%

XML

DEBT - Senior Unsecured Notes (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Oct. 07, 2019	May 29, 2019
Debt Instrument [Line Items]
Premium, net	$ 6,740,000
Deferred financing costs	18,418,000
Senior Notes
Debt Instrument [Line Items]
Principal balance	1,250,000,000	$ 1,250,000,000
Premium, net	6,740,000	7,600,000
Deferred financing costs	8,416,000	8,800,000
Senior Notes | 4.80% senior unsecured notes due 2024 (“2024 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 300,000,000	300,000,000
Interest rate	4.80%			4.80%
Senior Notes | 5.125% senior unsecured notes due 2026 (“2026 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 500,000,000	500,000,000
Interest rate	5.125%
Senior Notes | 5.88% senior unsecured notes due 2027 (“2027 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 100,000,000	100,000,000
Interest rate	5.88%
Senior Notes | 3.90% senior unsecured notes due 2029 (“2029 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 350,000,000	$ 350,000,000
Interest rate	3.90%		3.90%

XML

DEBT - Narrative (Details)				3 Months Ended		9 Months Ended
	Aug. 01, 2020 USD ($) property	Apr. 01, 2020 USD ($) property	Sep. 09, 2019 USD ($) extensionOption	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 CAD ($)	Dec. 31, 2019 USD ($)	Oct. 07, 2019	Sep. 09, 2019 CAD ($) extensionOption	May 29, 2019
Debt Instrument [Line Items]
Number of properties sold securing debt | property	1	2
Aggregate amount of secured debt assumed by buyer	$ 17,600,000	$ 14,200,000
Amount outstanding under credit facility				$ 56,000,000		$ 56,000,000			$ 0
Interest expense				24,904,000	$ 29,255,000	75,900,000	$ 99,181,000
Non-cash interest expense				2,100,000	$ 2,500,000	6,527,000	$ 7,846,000
Accrued interest				18,100,000		18,100,000			16,700,000
Fifth Amended and Restated Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Borrowing capacity			$ 2,750,000,000
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity			1,000,000,000.0
Borrowing capacity in certain foreign currencies (up to)			$ 175,000,000.0
Number of extension options | extensionOption			2								2
Extension period			6 months
Amount outstanding under credit facility				56,000,000.0		56,000,000.0
Available borrowing capacity				$ 944,000,000.0		$ 944,000,000.0
Interest rate				1.25%		1.25%		1.25%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Annum percent unused borrowing fee			0.125%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Annum percent unused borrowing fee			0.30%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			1.00%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.00%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			0.45%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.775%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.45%
Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount				$ 1,250,000,000		$ 1,250,000,000			$ 1,250,000,000
Senior Notes | 4.80% senior unsecured notes due 2024 (“2024 Notes”)
Debt Instrument [Line Items]
Interest rate				4.80%		4.80%		4.80%				4.80%
Senior Notes | 3.90% senior unsecured notes due 2029 (“2029 Notes”)
Debt Instrument [Line Items]
Interest rate				3.90%		3.90%		3.90%		3.90%
Senior Notes | 5.125% senior unsecured notes due 2026 (“2026 Notes”)
Debt Instrument [Line Items]
Interest rate				5.125%		5.125%		5.125%
Senior Notes | 5.88% senior unsecured notes due 2027 (“2027 Notes”)
Debt Instrument [Line Items]
Interest rate				5.88%		5.88%		5.88%
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount			$ 845,000,000.0					$ 955,000,000.0
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap			1.24%								1.24%
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.00%
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			0.65%
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.85%
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.65%
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | Redemption Period One
Debt Instrument [Line Items]
Aggregate principal amount			$ 105,000,000.0
U.S. Dollar Term Loan | Fifth Amended and Restated Credit Agreement | Redemption Period Two
Debt Instrument [Line Items]
Aggregate principal amount			$ 350,000,000.0
Canadian Dollar Term Loan | Fifth Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount											$ 125,000,000.0
Canadian Dollar Term Loan | Fifth Amended and Restated Credit Agreement | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap			0.93%								0.93%
Canadian Dollar Term Loan | Fifth Amended and Restated Credit Agreement | CDOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.85%
Canadian Dollar Term Loan | Fifth Amended and Restated Credit Agreement | CDOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.65%

XML

DEBT - Schedule of Maturities for Outstanding Debt (Details) $ in Thousands	Sep. 09, 2019 extensionOption	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
October 1 through December 31, 2020		$ 655
2021		17,689
2022		107,412
2023		408,478
2024		896,083
Thereafter		1,004,345
Total Debt		2,434,662
Premium, net		6,740
Deferred financing costs, net		(18,418)
Long-term Debt		2,422,984
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Number of extension options | extensionOption	2
Extension period	6 months
Secured Indebtedness
Debt Instrument [Line Items]
October 1 through December 31, 2020		655
2021		17,689
2022		2,412
2023		2,478
2024		2,545
Thereafter		54,345
Total Debt		80,124
Premium, net		0
Deferred financing costs, net		(1,149)	$ (1,700)
Long-term Debt		78,975
Revolving Credit Facility
Debt Instrument [Line Items]
October 1 through December 31, 2020		0
2021		0
2022		0
2023		56,000
2024		0
Thereafter		0
Total Debt		56,000
Premium, net		0
Deferred financing costs, net		0
Long-term Debt		56,000
Term Loans
Debt Instrument [Line Items]
October 1 through December 31, 2020		0
2021		0
2022		105,000
2023		350,000
2024		593,538
Thereafter		0
Total Debt		1,048,538
Premium, net		0
Deferred financing costs, net		(8,853)
Long-term Debt		1,039,685
Senior Notes
Debt Instrument [Line Items]
October 1 through December 31, 2020		0
2021		0
2022		0
2023		0
2024		300,000
Thereafter		950,000
Total Debt		1,250,000
Premium, net		6,740	7,600
Deferred financing costs, net		(8,416)	$ (8,800)
Long-term Debt		$ 1,248,324

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2019 USD ($) derivative	Sep. 30, 2020 USD ($) derivative	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) derivative	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)
Derivative [Line Items]
Fair value of derivatives in a net liability position		$ 40,138,000		$ 40,138,000		$ 626,000
Forward Starting Interest Rate Swaps
Derivative [Line Items]
Number of derivative contracts terminated | derivative	3
Payment to counterparties upon termination of derivatives	$ 12,600,000
Credit Risk
Derivative [Line Items]
Fair value of derivatives in a net liability position		34,300,000		34,300,000
Termination value		32,700,000		32,700,000
Cash Flow Hedges | Interest Rate Swap
Derivative [Line Items]
Ineffectiveness on cash flow hedges		0	$ 0	0	$ 0
Designated as Hedging Instrument
Derivative [Line Items]
Fair value of derivatives in a net liability position		$ 133,676,000		133,676,000		$ 96,651,000
Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Losses included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months				$ 12,500,000
Not Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Number of derivative instruments held | derivative		1		1
Fair value of derivative asset		$ 300,000		$ 300,000
Other expense related to derivatives		$ 100,000	$ 38,000		$ 31,000
Other income related to derivatives				$ 13,000

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details)	Jan. 31, 2023 USD ($)	Sep. 30, 2020 USD ($) derivative	Sep. 30, 2020 CAD ($) derivative	Dec. 31, 2019 USD ($)	Dec. 31, 2019 CAD ($)
Designated as Hedging Instrument | Net Investment Hedges
Derivative [Line Items]
Notional amount			$ 125,000,000		$ 125,000,000
Cross Currency Interest Rate Swaps | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Notional amount		$ 1,340,000,000	250,000,000	$ 1,490,000,000	125,000,000
Cross Currency Interest Rate Swaps | Designated as Hedging Instrument | Net Investment Hedges
Derivative [Line Items]
Notional amount			$ 53,239,000		54,489,000
Cross Currency Interest Rate Swaps | Not Designated as Hedging Instrument
Derivative [Line Items]
Number of derivative instruments held | derivative		1	1
Cross Currency Interest Rate Swaps | Not Designated as Hedging Instrument | Net Investment Hedges
Derivative [Line Items]
Notional amount			$ 3,061,000		$ 1,811,000
Cross Currency Interest Rate Contract with Accreting Balance | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Notional amount		$ 400,000,000.0
Cross Currency Interest Rate Contract with Accreting Balance | Designated as Hedging Instrument | Cash Flow Hedges | Forecast
Derivative [Line Items]
Notional amount	$ 600,000,000.0
Forward Starting Interest Rate Swaps - Effective January 2021 | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Notional amount			$ 125,000,000.0
Number of derivative instruments held | derivative		2	2
Forward Starting Interest Rate Collar - Effective January 2021 | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Number of derivative instruments held | derivative		1	1
Forward Starting Interest Rate Swap - Effective May 2024 | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Notional amount		$ 250,000,000.0
Number of derivative instruments held | derivative		6	6
Forward Starting Interest Rate Swaps And Forward Starting Interest Rate Collars | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Notional amount		$ 245,000,000.0

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) $ in Thousands	Sep. 30, 2020 USD ($) instrument	Dec. 31, 2019 USD ($)
Assets:
Fair Value	$ 8,473	$ 7,477
Liabilities:
Fair Value	40,138	626
Designated as Hedging Instrument
Assets:
Fair Value	8,473	7,477
Liabilities:
Fair Value	$ 133,676	96,651
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	0
Fair Value	$ 0	4,239
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts payable and accrued liabilities
Liabilities:
Count | instrument	11
Fair Value	$ 28,494	0
Designated as Hedging Instrument | Forward starting interest rate swaps | Cash flow | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	6
Fair Value	$ 3,840	0
Designated as Hedging Instrument | Forward starting interest rate swaps | Cash flow | Accounts payable and accrued liabilities
Liabilities:
Count | instrument	4
Fair Value	$ 10,742	494
Designated as Hedging Instrument | Cross currency interest rate swaps | Net investment | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	2
Fair Value	$ 4,633	3,238
Designated as Hedging Instrument | Forward starting interest rate collars | Cash flow | Accounts payable and accrued liabilities
Liabilities:
Count | instrument	1
Fair Value	$ 902	132
Designated as Hedging Instrument | CAD term loan | Net investment | Term loans, net
Liabilities:
Count | instrument	1
Fair Value	$ 93,538	$ 96,025

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain in other comprehensive (loss) income, cash flow hedges and net investment hedges	$ 879	$ (5,835)	$ (38,794)	$ (30,636)
Interest rate products
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, cash flow hedges	3,836	(8,196)	(42,826)	(27,933)
Interest rate products | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from accumulated other comprehensive income into income, cash flow hedges	(2,985)	1,173	(5,148)	4,781
Foreign currency products
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, net investment hedges	(1,044)	1,273	1,544	(3)
CAD term loan
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, net investment hedges	$ (1,913)	$ 1,088	$ 2,488	$ (2,700)

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Offsetting Assets:
Gross amounts of recognized assets	$ 8,473	$ 7,477
Gross amounts offset in the balance sheet, assets	0	0
Net amounts of assets presented in the balance sheet	8,473	7,477
Financial instruments, assets	(7,405)	(544)
Cash collateral received, assets	0	0
Net amount, assets	1,068	6,933
Offsetting Liabilities:
Gross amounts of recognized liabilities	40,138	626
Gross amounts offset in the balance sheet, liabilities	0	0
Liabilities presented in the balance sheet	40,138	626
Financial instruments, liabilities	(7,405)	(544)
Cash collateral received, liabilities	0	0
Net amount, liabilities	$ 32,733	$ 82

XML

FAIR VALUE DISCLOSURES - Narrative (Details) - Discount Rate	Sep. 30, 2020
Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Loans receivable, measurement input	0.06
Preferred equity investments, measurement input	0.10
Minimum | Secured Indebtedness
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt, measurement input	0.02
Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Loans receivable, measurement input	0.16
Preferred equity investments, measurement input	0.15
Maximum | Secured Indebtedness
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt, measurement input	0.03
Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Loans receivable, measurement input	0.12
Preferred equity investments, measurement input	0.11
Weighted Average | Secured Indebtedness
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt, measurement input	0.03

XML

FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Financial assets:
Loans receivable	$ 66,316,000	$ 67,527,000
Preferred equity investments	42,533,000	43,893,000
Senior Notes
Financial liabilities:
Financial liabilities	1,250,000,000	1,250,000,000
Secured Indebtedness
Financial liabilities:
Financial liabilities	80,124,000	114,777,000
Carrying Amount
Financial assets:
Loans receivable	61,076,000	63,070,000
Preferred equity investments	42,744,000	44,304,000
Carrying Amount | Senior Notes
Financial liabilities:
Financial liabilities	1,248,324,000	1,248,773,000
Carrying Amount | Secured Indebtedness
Financial liabilities:
Financial liabilities	78,975,000	113,070,000
Fair Value
Financial assets:
Loans receivable	56,956,000	59,832,000
Preferred equity investments	43,039,000	44,493,000
Fair Value | Senior Notes
Financial liabilities:
Financial liabilities	1,311,354,000	1,328,714,000
Fair Value | Secured Indebtedness
Financial liabilities:
Financial liabilities	$ 79,249,000	$ 105,510,000

XML

FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	$ 56,956	$ 59,832
Preferred equity investments	43,039	44,493
Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,311,354	1,328,714
Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	79,249	$ 105,510
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,311,354
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	56,956
Preferred equity investments	43,039
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	79,249
Measured on a Recurring Basis | Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	56,956
Preferred equity investments	43,039
Measured on a Recurring Basis | Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,311,354
Measured on a Recurring Basis | Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 79,249

XML

FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 8,473	$ 7,477
Financial liabilities	40,138	$ 626
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Financial liabilities	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward starting interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	28,494
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	4,633
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3,840
Financial liabilities	10,742
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Forward starting interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	902
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Forward starting interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Total | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	28,494
Measured on a Recurring Basis | Total | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	4,633
Measured on a Recurring Basis | Total | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3,840
Financial liabilities	10,742
Measured on a Recurring Basis | Total | Forward starting interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 902

XML

EQUITY - Common Stock (Details) - USD ($)		3 Months Ended	9 Months Ended
	Dec. 11, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax withholding obligations incurred on behalf of employees			$ 900,000	$ 1,300,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued upon vesting (in shares)			164,224
ATM Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds possible from sales of common stock under equity distribution agreement (up to)	$ 400,000,000.0
Shares sold under the ATM Program (in shares)		1,400,000	1,600,000
Sale of stock, average price per share (in dollars per share)		$ 15.70	$ 16.26
Gross proceeds from issuance of common stock		$ 21,400,000	$ 25,300,000
Payments for stock issuance commissions		300,000	400,000
Amount available under ATM Program		$ 314,700,000	$ 314,700,000

XML

EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares				3 Months Ended		9 Months Ended
	Aug. 05, 2020	May 06, 2020	Feb. 04, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Equity [Abstract]
Common dividends (in dollars per share)	$ 0.30	$ 0.30	$ 0.45	$ 0.30	$ 0.45	$ 1.05	$ 1.35

XML

EQUITY - Accumulated Other Comprehensive (Loss) Income (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	$ 3,364,340	$ 3,361,251	$ 3,488,460	$ 3,282,417	$ 3,260,376	$ 3,254,747
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(49,170)	$ (55,641)	(12,388)	$ (19,395)	$ (10,936)	$ 12,301
Foreign currency translation loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(702)		(1,516)
Unrealized loss on cash flow hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	$ (48,468)		$ (10,872)

XML

EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator
Net income attributable to common stockholders	$ 36,460	$ 23,282	$ 101,300	$ 29,255
Denominator
Basic weighted average common shares and common equivalents (in shares)	205,791,699	190,650,400	205,592,806	183,578,254
Dilutive restricted stock units (in shares)	935,468	1,301,989	849,868	1,120,157
Diluted weighted average common shares (in shares)	206,727,167	191,952,389	206,442,674	184,698,411
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 0.18	$ 0.12	$ 0.49	$ 0.16
Diluted common share (in dollars per share)	$ 0.18	$ 0.12	$ 0.49	$ 0.16

XML

EARNINGS PER COMMON SHARE - Narrative (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)	99,700	0	113,300	430

XML

SUBSEQUENT EVENTS (Details) - $ / shares					3 Months Ended		9 Months Ended
	Nov. 05, 2020	Aug. 05, 2020	May 06, 2020	Feb. 04, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)		$ 0.30	$ 0.30	$ 0.45	$ 0.30	$ 0.45	$ 1.05	$ 1.35
Subsequent Event
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)	$ 0.30